Tumors or cancer of the human BREAST.
Metastatic breast cancer characterized by EDEMA and ERYTHEMA of the affected breast due to LYMPHATIC METASTASIS and eventual obstruction of LYMPHATIC VESSELS by the cancer cells.
Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.
In humans, one of the paired regions in the anterior portion of the THORAX. The breasts consist of the MAMMARY GLANDS, the SKIN, the MUSCLES, the ADIPOSE TISSUE, and the CONNECTIVE TISSUES.
Any neoplasms of the male breast. These occur infrequently in males in developed countries, the incidence being about 1% of that in females.
An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST.
Pathological processes of the BREAST.
The nursing of an infant at the breast.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important.
Radiographic examination of the breast.
Neoplasms containing cyst-like formations or producing mucin or serum.
A cell line derived from cultured tumor cells.
A common and benign breast disease characterized by varying degree of fibrocystic changes in the breast tissue. There are three major patterns of morphological changes, including FIBROSIS, formation of CYSTS, and proliferation of glandular tissue (adenosis). The fibrocystic breast has a dense irregular, lumpy, bumpy consistency.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.
A cell surface protein-tyrosine kinase receptor that is overexpressed in a variety of ADENOCARCINOMAS. It has extensive homology to and heterodimerizes with the EGF RECEPTOR, the ERBB-3 RECEPTOR, and the ERBB-4 RECEPTOR. Activation of the erbB-2 receptor occurs through heterodimer formation with a ligand-bound erbB receptor family member.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Implants used to reconstruct and/or cosmetically enhance the female breast. They have an outer shell or envelope of silicone elastomer and are filled with either saline or silicone gel. The outer shell may be either smooth or textured.
Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
The inspection of one's breasts, usually for signs of disease, especially neoplastic disease.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Tumors or cancer of the SKIN.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.
DNA present in neoplastic tissue.
A noninvasive (noninfiltrating) carcinoma of the breast characterized by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)
Surgical procedure to remove one or both breasts.
An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)
Tumors or cancer of the LUNG.
Tumors or cancers of the KIDNEY.
A infiltrating (invasive) breast cancer, relatively uncommon, accounting for only 5%-10% of breast tumors in most series. It is often an area of ill-defined thickening in the breast, in contrast to the dominant lump characteristic of ductal carcinoma. It is typically composed of small cells in a linear arrangement with a tendency to grow around ducts and lobules. There is likelihood of axillary nodal involvement with metastasis to meningeal and serosal surfaces. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1205)
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
Tumors or cancer located in bone tissue or specific BONES.
Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system.
Use of ultrasound for imaging the breast. The most frequent application is the diagnosis of neoplasms of the female breast.
Tumors or cancer of the THYROID GLAND.
Studies which start with the identification of persons with a disease of interest and a control (comparison, referent) group without the disease. The relationship of an attribute to the disease is examined by comparing diseased and non-diseased persons with regard to the frequency or levels of the attribute in each group.
A tumor suppressor gene (GENES, TUMOR SUPPRESSOR) located on human CHROMOSOME 17 at locus 17q21. Mutations of this gene are associated with the formation of HEREDITARY BREAST AND OVARIAN CANCER SYNDROME. It encodes a large nuclear protein that is a component of DNA repair pathways.
Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
Experimentally induced mammary neoplasms in animals to provide a model for studying human BREAST NEOPLASMS.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Tumors or cancer of the LIVER.
Tumors, cancer or other neoplasms produced by exposure to ionizing or non-ionizing radiation.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
The physiological period following the MENOPAUSE, the permanent cessation of the menstrual life.
An adenoma containing fibrous tissue. It should be differentiated from ADENOFIBROMA which is a tumor composed of connective tissue (fibroma) containing glandular (adeno-) structures. (From Dorland, 27th ed)
Tumors or cancer of the PAROTID GLAND.
Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.
Removal of only enough breast tissue to ensure that the margins of the resected surgical specimen are free of tumor.
A benign neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. In some instances, considerable portions of the neoplasm, or even the entire mass, may be cystic. (Stedman, 25th ed)
Surgical reconstruction of the breast including both augmentation and reduction.
Neoplasms developing from some structure of the connective and subcutaneous tissue. The concept does not refer to neoplasms located in connective or soft tissue.
Neoplasms associated with a proliferation of a single clone of PLASMA CELLS and characterized by the secretion of PARAPROTEINS.
A fluid-filled closed cavity or sac that is lined by an EPITHELIUM and found in the BREAST. It may appear as a single large cyst in one breast, multifocal, or bilateral in FIBROCYSTIC BREAST DISEASE.
Tumors or cancer of the APPENDIX.
A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane.
Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.
The conic organs which usually give outlet to milk from the mammary glands.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Compounds that interact with ESTROGEN RECEPTORS in target tissues to bring about the effects similar to those of ESTRADIOL. Estrogens stimulate the female reproductive organs, and the development of secondary female SEX CHARACTERISTICS. Estrogenic chemicals include natural, synthetic, steroidal, or non-steroidal compounds.
Removal and examination of tissue obtained through a transdermal needle inserted into the specific region, organ, or tissue being analyzed.
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
One of the ESTROGEN RECEPTORS that has marked affinity for ESTRADIOL. Its expression and function differs from, and in some ways opposes, ESTROGEN RECEPTOR BETA.
A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)
Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Tumors or cancer of the ENDOCRINE GLANDS.
An estrogen responsive cell line derived from a patient with metastatic human breast ADENOCARCINOMA (at the Michigan Cancer Foundation.)
Glandular tissue in the BREAST of human that is under the influence of hormones such as ESTROGENS; PROGESTINS; and PROLACTIN. In WOMEN, after PARTURITION, the mammary glands secrete milk (MILK, HUMAN) for the nourishment of the young.
A multilocular tumor with mucin secreting epithelium. They are most often found in the ovary, but are also found in the pancreas, appendix, and rarely, retroperitoneal and in the urinary bladder. They are considered to have low-grade malignant potential.
The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases, new or old, in the population at a given time.
The period before MENOPAUSE. In premenopausal women, the climacteric transition from full sexual maturity to cessation of ovarian cycle takes place between the age of late thirty and early fifty.
Elements of limited time intervals, contributing to particular results or situations.
A malignant epithelial tumor with a glandular organization.
Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
Neoplasms composed of vascular tissue. This concept does not refer to neoplasms located in blood vessels.
Tumors or cancer of the SALIVARY GLANDS.
Tumors or cancer of the EYE.
Tumors or cancer of the UTERUS.
Experimental transplantation of neoplasms in laboratory animals for research purposes.
Area of the human body underneath the SHOULDER JOINT, also known as the armpit or underarm.
The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age.
Certain tumors that 1, arise in organs that are normally dependent on specific hormones and 2, are stimulated or caused to regress by manipulation of the endocrine environment.
Surgical insertion of an inert sac filled with silicone or other material to augment the female form cosmetically.
Tumors or cancer of the NOSE.
Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.
A large, nuclear protein, encoded by the BRCA2 gene (GENE, BRCA2). Mutations in this gene predispose humans to breast and ovarian cancer. The BRCA2 protein is an essential component of DNA repair pathways, suppressing the formation of gross chromosomal rearrangements. (from Genes Dev. 2000;14(11):1400-6)
Tumors or cancer of the COLON.
An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)
The determination of the pattern of genes expressed at the level of GENETIC TRANSCRIPTION, under specific circumstances or in a specific cell.
Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.
The phosphoprotein encoded by the BRCA1 gene (GENE, BRCA1). In normal cells the BRCA1 protein is localized in the nucleus, whereas in the majority of breast cancer cell lines and in malignant pleural effusions from breast cancer patients, it is localized mainly in the cytoplasm. (Science 1995;270(5237):713,789-91)
RNA present in neoplastic tissue.
Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.
Malignant neoplasms involving the ductal systems of any of a number of organs, such as the MAMMARY GLANDS, the PANCREAS, the PROSTATE, or the LACRIMAL GLAND.
A latent susceptibility to disease at the genetic level, which may be activated under certain conditions.
Neoplasms composed of muscle tissue: skeletal, cardiac, or smooth. The concept does not refer to neoplasms located in muscles.
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
A benign epithelial tumor with a glandular organization.
Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
A tumor suppressor gene (GENES, TUMOR SUPPRESSOR) located on human chromosome 13 at locus 13q12.3. Mutations in this gene predispose humans to breast and ovarian cancer. It encodes a large, nuclear protein that is an essential component of DNA repair pathways, suppressing the formation of gross chromosomal rearrangements. (from Genes Dev 2000;14(11):1400-6)
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)
A general term for various neoplastic diseases of the lymphoid tissue.
Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time.
Tumors or cancer of the INTESTINES.
Methods which attempt to express in replicable terms the level of CELL DIFFERENTIATION in neoplasms as increasing ANAPLASIA correlates with the aggressiveness of the neoplasm.
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
Neoplasms located in the bone marrow. They are differentiated from neoplasms composed of bone marrow cells, such as MULTIPLE MYELOMA. Most bone marrow neoplasms are metastatic.
The probability that an event will occur. It encompasses a variety of measures of the probability of a generally unfavorable outcome.
Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.
Neoplasms composed of sebaceous or sweat gland tissue or tissue of other skin appendages. The concept does not refer to neoplasms located in the sebaceous or sweat glands or in the other skin appendages.
The erbB-2 gene is a proto-oncogene that codes for the erbB-2 receptor (RECEPTOR, ERBB-2), a protein with structural features similar to the epidermal growth factor receptor. Its name originates from the viral oncogene homolog (v-erbB) which is a truncated form of the chicken erbB gene found in the avian erythroblastosis virus. Overexpression and amplification of the gene is associated with a significant number of adenocarcinomas. The human c-erbB-2 gene is located at 17q21.2.
Neoplasms located in the vasculature system, such as ARTERIES and VEINS. They are differentiated from neoplasms of vascular tissue (NEOPLASMS, VASCULAR TISSUE), such as ANGIOFIBROMA or HEMANGIOMA.
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
Neoplasms composed of more than one type of neoplastic tissue.
Organized periodic procedures performed on large groups of people for the purpose of detecting disease.
Compounds that inhibit AROMATASE in order to reduce production of estrogenic steroid hormones.
Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988)
Tumors or cancer of the PALATE, including those of the hard palate, soft palate and UVULA.
A CELL CYCLE and tumor growth marker which can be readily detected using IMMUNOCYTOCHEMISTRY methods. Ki-67 is a nuclear antigen present only in the nuclei of cycling cells.
The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.
A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)
Tumors or cancer of the MANDIBLE.
A benign neoplasm composed of glandular and fibrous tissues, with a relatively large proportion of glands. (Stedman, 25th ed)
Tumors or cancer of the THYMUS GLAND.
Tumors or cancer of the SPLEEN.
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.
Tumors or cancer of the BILE DUCTS.
Tumors in any part of the heart. They include primary cardiac tumors and metastatic tumors to the heart. Their interference with normal cardiac functions can cause a wide variety of symptoms including HEART FAILURE; CARDIAC ARRHYTHMIAS; or EMBOLISM.
The simultaneous analysis of multiple samples of TISSUES or CELLS from BIOPSY or in vitro culture that have been arranged in an array format on slides or microchips.
The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.
Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord.
A cystic tumor of the ovary, containing thin, clear, yellow serous fluid and varying amounts of solid tissue, with a malignant potential several times greater than that of mucinous cystadenoma (CYSTADENOMA, MUCINOUS). It can be unilocular, parvilocular, or multilocular. It is often bilateral and papillary. The cysts may vary greatly in size. (Dorland, 27th ed; from Hughes, Obstetric-Gynecologic Terminology, 1972)
Persons who have experienced a prolonged survival after serious disease or who continue to live with a usually life-threatening condition as well as family members, significant others, or individuals surviving traumatic life events.
They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system.
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
Diseases of the domestic dog (Canis familiaris). This term does not include diseases of wild dogs, WOLVES; FOXES; and other Canidae for which the heading CARNIVORA is used.
The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.
Cancer or tumors of the MAXILLA or upper jaw.
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.
Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS.
A rare malignant neoplasm characterized by rapidly proliferating, extensively infiltrating, anaplastic cells derived from blood vessels and lining irregular blood-filled or lumpy spaces. (Stedman, 25th ed)
Tumors or cancer of the anal gland.
In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.
Antibodies produced by a single clone of cells.
Tumors or cancer of the STOMACH.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
The ratio of two odds. The exposure-odds ratio for case control data is the ratio of the odds in favor of exposure among cases to the odds in favor of exposure among noncases. The disease-odds ratio for a cohort or cross section is the ratio of the odds in favor of disease among the exposed to the odds in favor of disease among the unexposed. The prevalence-odds ratio refers to an odds ratio derived cross-sectionally from studies of prevalent cases.
Neoplasms composed of fatty tissue or connective tissue made up of fat cells in a meshwork of areolar tissue. The concept does not refer to neoplasms located in adipose tissue.
Any detectable and heritable alteration in the lineage of germ cells. Mutations in these cells (i.e., "generative" cells ancestral to the gametes) are transmitted to progeny while those in somatic cells are not.
A type of IN SITU HYBRIDIZATION in which target sequences are stained with fluorescent dye so their location and size can be determined using fluorescence microscopy. This staining is sufficiently distinct that the hybridization signal can be seen both in metaphase spreads and in interphase nuclei.
The statistical reproducibility of measurements (often in a clinical context), including the testing of instrumentation or techniques to obtain reproducible results. The concept includes reproducibility of physiological measurements, which may be used to develop rules to assess probability or prognosis, or response to a stimulus; reproducibility of occurrence of a condition; and reproducibility of experimental results.
A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.
Tumors or cancer of the DUODENUM.
Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.
Total mastectomy with axillary node dissection, but with preservation of the pectoral muscles.
An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.
Tumors or cancer of the MOUTH.
Using fine needles (finer than 22-gauge) to remove tissue or fluid specimens from the living body for examination in the pathology laboratory and for disease diagnosis.
Hybridization of a nucleic acid sample to a very large set of OLIGONUCLEOTIDE PROBES, which have been attached individually in columns and rows to a solid support, to determine a BASE SEQUENCE, or to detect variations in a gene sequence, GENE EXPRESSION, or for GENE MAPPING.
A selective increase in the number of copies of a gene coding for a specific protein without a proportional increase in other genes. It occurs naturally via the excision of a copy of the repeating sequence from the chromosome and its extrachromosomal replication in a plasmid, or via the production of an RNA transcript of the entire repeating sequence of ribosomal RNA followed by the reverse transcription of the molecule to produce an additional copy of the original DNA sequence. Laboratory techniques have been introduced for inducing disproportional replication by unequal crossing over, uptake of DNA from lysed cells, or generation of extrachromosomal sequences from rolling circle replication.
Tumors or cancers of the ADRENAL CORTEX.
Carbohydrate antigen elevated in patients with tumors of the breast, ovary, lung, and prostate as well as other disorders. The mucin is expressed normally by most glandular epithelia but shows particularly increased expression in the breast at lactation and in malignancy. It is thus an established serum marker for breast cancer.
Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, immunotherapy, hyperthermia, etc.) that precedes a necessary second modality of treatment.
Statistical models used in survival analysis that assert that the effect of the study factors on the hazard rate in the study population is multiplicative and does not change over time.
Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER.
Tumors or cancer of the MEDIASTINUM.
Tumors or cancer of the URINARY BLADDER.
Transplantation between animals of different species.
Pathological processes that tend eventually to become malignant. (From Dorland, 27th ed)
A structurally diverse group of compounds distinguished from ESTROGENS by their ability to bind and activate ESTROGEN RECEPTORS but act as either an agonist or antagonist depending on the tissue type and hormonal milieu. They are classified as either first generation because they demonstrate estrogen agonist properties in the ENDOMETRIUM or second generation based on their patterns of tissue specificity. (Horm Res 1997;48:155-63)
A Janus kinase subtype that is involved in signaling from GROWTH HORMONE RECEPTORS; PROLACTIN RECEPTORS; and a variety of CYTOKINE RECEPTORS such as ERYTHROPOIETIN RECEPTORS and INTERLEUKIN RECEPTORS. Dysregulation of Janus kinase 2 due to GENETIC TRANSLOCATIONS have been associated with a variety of MYELOPROLIFERATIVE DISORDERS.
Neoplasms composed of cells from the deepest layer of the epidermis. The concept does not refer to neoplasms located in the stratum basale.

Diphtheria toxin effects on human cells in tissue culture. (1/42895)

HeLa cells exposed to a single sublethal concentration of diphtheria toxin were found to have diminished sensitivity when subsequently reexposed to the toxin. Three cells strains exhibiting toxin resistance were developed. In the cells that had previously been exposed to toxin at 0.015 mug/ml, 50% inhibition of protein synthesis required a toxin concentration of 0.3 mug/ml, which is more than 10 times that required in normal HeLa cells. There appears to be a threshold level of diphtheria toxin action. Concentrations of toxin greater than that required for 50% inhibition of protein synthesis (0.01 mug/ml) are associated with cytotoxicity, whereas those below this concentration may not be lethal. Several established human cell lines of both normal and neoplastic origin were tested for their sensitivity to the effects of the toxin. No special sensitivity was observed with the cells of tumor origin. Fifty % inhibition of protein synthesis of HeLa cells was achieved with diphtheria toxin (0.01 mug/ml) as compared to the normal human cell lines tested (0.03 and 0.5 mug/ml) and a cell line derived from a human pancreatic adenocarcinoma (0.2 mug/ml). A human breast carcinoma cell line showed a maximum of 45% inhibition of protein synthesis. This required a diphtheria toxin concentration of 5 mug/ml. These results suggest that different human cell lines show wide variation in their sensitivity to the toxin.  (+info)

The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. (2/42895)

We have established or characterized six lines of human breast cancer maintained in long-term tissue culture for at least 1 year and have examined these lines for estrogen responsiveness. One of these cell lines, MCF-7, shows marked stimulation of macromolecular synthesis and cell division with physiological concentrations of estradiol. Antiestrogens are strongly inhibitory, and at concentrations greater than 3 X 10(-7) M they kill cells. Antiestrogen effects are prevented by simultaneous treatment with estradiol or reversed by addition of estradiol to cells incubated in antiestrogen. Responsive cell lines contain high-affinity specific estradiol receptors. Antiestrogens compete with estradiol for these receptors but have a lower apparent affinity for the receptor than estrogens. Stimulation of cells by estrogens is biphasic, with inhibition and cell death at concentrations of 17beta-estradiol or diethylstilbestrol exceeding 10(-7) M. Killing by high concentrations of estrogen is probably a nonspecific effect in that we observe this response with 17alpha-estradiol at equivalent concentrations and in the otherwise unresponsive cells that contain no estrogen receptor sites.  (+info)

The effects of glucocorticoids and progesterone on hormone-responsive human breast cancer in long-term tissue culture. (3/42895)

Glucocorticoids, at physiological concentration, inhibit cell division and thymidine incorporation in three lines of human breast cancer maintained in long-term tissue culture. At steroid concentrations sufficient to inhibit thymidine incorporation 50%, little or no effect is seen on protein synthesis 48 hr after hormone addition. All three of these lines are shown to have glucocorticoid receptors demonstrable by competitive protein binding assays. Receptors are extensively characterized in one line by sucrose density gradient analysis and binding specificity studies. Good correlation between receptor-binding specificity and biological activity is found except for progesterone, which binds to glucocorticoid receptor but is noninhibitory. Cross-competition and quantification studies demonstrate a separate receptor for progesterone. This receptor has limited binding specificities restricted largely to progestational agents, whereas the glucocorticoid receptor bound both glucocorticoids and progesterone. Two other human breast cancer lines neither contain glucocorticoid receptor nor are inhibited by glucocorticoids. It is concluded that in some cases glucocorticoids can directly limit growth in human breast cancer in vitro without requiring alterations in other trophic hormones.  (+info)

The effects of androgens and antiandrogens on hormone-responsive human breast cancer in long-term tissue culture. (4/42895)

We have examined five human breast cancer cell lines in continuous tissue culture for androgen responsiveness. One of these cell lines shows a 2- to 4-fold stimulation of thymidine incorporation into DNA, apparent as early as 10 hr following androgen addition to cells incubated in serum-free medium. This stimulation is accompanied by an acceleration in cell replication. Antiandrogens [cyproterone acetate (6-chloro-17alpha-acetate-1,2alpha-methylene-4,6-pregnadiene-3,20-dione) and R2956 (17beta-hydroxy-2,2,17alpha-trimethoxyestra-4,9,11-triene-1-one)] inhibit both protein and DNA synthesis below control levels and block androgen-mediated stimulation. Prolonged incubation (greater than 72 hr) in antiandrogen is lethal. The MCF- cell line contains high-affinity receptors for androgenic steroids demonstrable by sucrose density gradients and competitive protein binding analysis. By cross-competition studies, androgen receptors are distinguishable from estrogen receptors also found in this cell line. Concentrations of steroid that saturate androgen receptor sites in vitro are about 1000 times lower than concentrations that maximally stimulate the cells. Changes in quantity and affinity of androgen binding to intact cells at 37 degrees as compared with usual binding techniques using cytosol preparation at 0 degrees do not explain this difference between dissociation of binding and effect. However, this difference can be explained by conversion of [3H]-5alpha-dihydrotestosterone to 5alpha-androstanediol and more polar metabolites at 37 degrees. An examination of incubation media, cytoplasmic extracts and crude nuclear pellets reveals probable conversion of [3H]testosterone to [3H]-5alpha-dihydrotestosterone. Our data provide compelling evidence that some human breast cancer, at least in vitro, may be androgen dependent.  (+info)

Activation of Src in human breast tumor cell lines: elevated levels of phosphotyrosine phosphatase activity that preferentially recognizes the Src carboxy terminal negative regulatory tyrosine 530. (5/42895)

Elevated levels of Src kinase activity have been reported in a number of human cancers, including colon and breast cancer. We have analysed four human breast tumor cell lines that exhibit high levels of Src kinase activity, and have determined that these cell lines also exhibit a high level of a phosphotyrosine phosphatase activity that recognizes the Src carboxy-terminal P-Tyr530 negative regulatory site. Total Src kinase activity in these cell lines is elevated as much as 30-fold over activity in normal control cells and specific activity is elevated as much as 5.6-fold. When the breast tumor cells were grown in the presence of the tyrosine phosphatase inhibitor vanadate, Src kinase activity was reduced in all four breast tumor cell lines, suggesting that Src was being activated by a phosphatase which could recognize the Tyr530 negative regulatory site. In fractionated cell extracts from the breast tumor cells, we found elevated levels of a membrane associated tyrosine phosphatase activity that preferentially dephosphorylated a Src family carboxy-terminal phosphopeptide containing the regulatory tyrosine 530 site. Src was hypophosphorylated in vivo at tyrosine 530 in at least two of the tumor cell lines, further suggesting that Src was being activated by a phosphatase in these cells. In preliminary immunoprecipitation and antibody depletion experiments, we were unable to correlate the major portion of this phosphatase activity with several known phosphatases.  (+info)

Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells. (6/42895)

Increased breast cancer growth has been associated with increased expression of epidermal growth factor receptor (EGFR) and ErbB2 receptor tyrosine kinases (RTKs). Upon activation, RTKs may transmit their oncogenic signals by binding to the growth factor receptor bound protein-2 (Grb2), which in turn binds to SOS and activates the Ras/Raf/MEK/mitogen-activated protein (MAP) kinase pathway. Grb2 is important for the transformation of fibroblasts by EGFR and ErbB2; however, whether Grb2 is also important for the proliferation of breast cancer cells expressing these RTKs is unclear. We have used liposomes to deliver nuclease-resistant antisense oligodeoxynucleotides (oligos) specific for the GRB2 mRNA to breast cancer cells. Grb2 protein downregulation could inhibit breast cancer cell growth; the degree of growth inhibition was dependent upon the activation and/or endogenous levels of the RTKs. Grb2 inhibition led to MAP kinase inactivation in EGFR, but not in ErbB2, breast cancer cells, suggesting that different pathways might be used by EGFR and ErbB2 to regulate breast cancer growth.  (+info)

Increased expression of fibroblast growth factor 8 in human breast cancer. (7/42895)

Fibroblast growth factor 8 (FGF8) is an important developmental protein which is oncogenic and able to cooperate with wnt-1 to produce mouse mammary carcinoma. The level of expression of FGF8 mRNA was measured in 68 breast cancers and 24 non-malignant breast tissues. Elevated levels of FGF8 mRNA were found in malignant compared to non-malignant breast tissues with significantly more malignant tissues expressing FGF8 (P=0.019) at significantly higher levels (P=0.031). In situ hybridization of breast cancer tissues and analysis of purified populations of normal epithelial cells and breast cancer cell lines showed that malignant epithelial cells expressed FGF8 mRNA at high levels compared to non-malignant epithelial and myoepithelial cells and fibroblasts. Although two of the receptors which FGF8 binds to (FGFR2-IIIc, FGFR3-IIIc) are not expressed in breast cancer cells, an autocrine activation loop is possible since expression of fibroblast growth factor receptor (FGFR) 4 and FGFR1 are retained in malignant epithelial cells. This is the first member of the FGF family to have increased expression in breast cancer and a potential autocrine role in its progression.  (+info)

Estrogen-dependent and independent activation of the P1 promoter of the p53 gene in transiently transfected breast cancer cells. (8/42895)

Loss of p53 function by mutational inactivation is the most common marker of the cancerous phenotype. Previous studies from our laboratory have demonstrated 17 beta estradiol (E2) induction of p53 protein expression in breast cancer cells. Although direct effects of E2 on the expression of p53 gene are not known, the steroid is a potent regulator of c-Myc transcription. In the present studies, we have examined the ability of E2 and antiestrogens to regulate the P1 promoter of the p53 gene which contains a c-Myc responsive element. Estrogen receptor (ER)-positive T47D and MCF-7 cells were transiently transfected with the P1CAT reporter plasmid and levels of CAT activity in response to serum, E2 and antiestrogens were monitored. Factors in serum were noted to be the dominant inducers of chloramphenicol acetyltransferase (CAT) expression in MCF-7 cells. The levels of CAT were drastically reduced when cells were maintained in serum free medium (SFM). However, a subtle ER-mediated induction of CAT expression was detectable when MCF-7 cells, cultured in SFM, were treated with E2. In serum-stimulated T47D cells, the CAT expression was minimal. The full ER antagonist, ICI 182 780 (ICI) had no effect. Treatment with E2 or 4-hydroxy tamoxifen (OHT) resulted in P1CAT induction; OHT was more effective than E2. Consistent with c-Myc regulation of the P1 promoter, E2 stimulated endogenous c-Myc in both cell lines. Two forms of c-Myc were expressed independent of E2 stimuli. The expression of a third more rapidly migrating form was E2-dependent and ER-mediated since it was blocked by the full ER antagonist, ICI, but not by the ER agonist/antagonist OHT. These data demonstrate both ER-mediated and ER-independent regulation of c-Myc and the P1 promoter of the p53 gene, and show differential effects of the two classes of antiestrogens in their ability to induce the P1 promoter of the p53 gene in breast cancer cells.  (+info)

RATIONALE: Drugs used in chemotherapy, such as docetaxel, fluorouracil, epirubicin hydrochloride, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether giving combination chemotherapy together with or without bevacizumab is more effective in treating patients with nonmetastatic breast cancer.. PURPOSE: This randomized phase III trial is studying how well giving combination chemotherapy works compared with giving combination chemotherapy together with bevacizumab in treating patients with nonmetastatic breast cancer. ...
TY - JOUR. T1 - Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer. T2 - Results of International Breast Cancer Study Group trial 15-95. AU - Basser, Russell L.. AU - ONeil, Anne. AU - Martinelli, Giovanni. AU - Green, Michael D.. AU - Peccatori, Fedro. AU - Cinieri, Severio. AU - Caotes, Alan S.. AU - Gelber, Richard D.. AU - Aebi, Stefan. AU - Castiglione-Gertsch, Monica. AU - Viale, Guiseppe. AU - Price, Karen N.. AU - Goldhirsch, Aron. PY - 2006/1/20. Y1 - 2006/1/20. N2 - Purpose: To compare adjuvant dose-intensive epirubicin and cyclophosphamide chemotherapy administered with filgrastim and progenitor cell support (DI-EC) with standard-dose anthracycline-based chemotherapy (SD-CT) for patients with early-stage breast cancer and a high risk of relapse, defined as stage II disease with 10 or more positive axillary nodes; or an estrogen receptor-negative or stage III tumor with five or more positive axillary nodes. Patients and Methods: Three hundred ...
Background: Young breast cancer occupies a higher and higher proportion of breast cancer, especially in Asia, and is associated with a more unfavorable prognosis compared with the disease arising in older women. However, the poor prognosis of young breast cancer cannot be fully explained by the clinical and molecular factors. Methods: This study investigated 1125 Chinese breast cancer patients diagnosed from 2009 to 2013. A data mining of gene expression profiles was performed for the young and older breast cancer patients, identifying significantly differentially expressed genes. Quantitative RT-PCR, Western blotting and immunohistochemistry assay were carried out for the clinical sample validations. Results: The investigation firstly displayed that young patients (≤45 years) accounted for 47.6 % (535/1125) of breast cancer, and clinically associated with some unfavorable factors related to poor prognosis, such as invasive pathological type, high tumor grade, lymph node positive, ER ...
Clinical trial for Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Stage II Breast Cancer | Triple Negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | Stage IA Breast Cancer , MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer
How long do people usually live with untreated breast cancer - How long do people usually live with untreated breast cancer? Variable. This is highly dependent on the cancer type and stage of presentation. Some aggressive forms of cancer may take over vital organs within months; other breast cancers may rarely spread to other organs and may be indolent for years and years. What remains true is that there is no benefit of watchful waiting when it comes to breast cancer: all else being equal, early diagnosis can save lives.
Title:Stemness Phenotype in Tamoxifen Resistant Breast Cancer Cells May be Induced by Interactions Between Receptor Tyrosine Kinases and ERα-66. VOLUME: 13 ISSUE: 3. Author(s):Leila Farahmand, Sepideh Mansouri, Narges Jafarbeik-Iravani, Azin Teymourzadeh and Keivan Majidzadeh-A*. Affiliation:Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Genetics Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran. Keywords:Alternative growth cascades, breast cancer, receptor tyrosine kinases, signaling pathways, stemness phenotype, tamoxifen resistance.. Abstract:Background: Tamoxifen is widely administered ...
Despite progress in the management of breast cancer, the molecular underpinnings of clinically aggressive subtypes of the disease are not well-understood. Here, we show that activation of Notch developmental signaling in estrogen receptor (ER)-negative breast cancer cells results in direct transcriptional up-regulation of the apoptosis inhibitor and cell cycle regulator survivin. This response is associated with increased expression of survivin at mitosis, enhanced cell proliferation, and heightened viability at cell division. Conversely, targeting Notch signaling with a peptidyl gamma-secretase inhibitor suppressed survivin levels, induced apoptosis, abolished colony formation in soft agar, and inhibited localized and metastatic tumor growth in mice, without organ or systemic toxicity. In contrast, ER+ breast cancer cells, or various normal cell types, were insensitive to Notch stimulation. Therefore, ER- breast cancer cells become dependent on Notch-survivin signaling for their maintenance, in vivo.
TY - JOUR. T1 - Competing Risk of Death in Elderly Patients with Newly Diagnosed Stage I Breast Cancer. AU - Wasif, Nabil. AU - Neville, Matthew. AU - Gray, Richard. AU - Cronin, Patricia. AU - Pockaj, Barbara A. PY - 2019/1/1. Y1 - 2019/1/1. N2 - Background: The majority of newly diagnosed breast cancers in the US are in women aged older than 65 years who can have additional comorbidities. Balancing the risks and benefits of treatment should take into account these competing risks of death. Study Design: The Surveillance, Epidemiology, and End Results Program-Medicare database was used to identify women with stage I breast cancer undergoing operations from 2004-2012. Using neural network analysis, comorbidities associated with mortality were grouped into clinically relevant categories. Cumulative incidence graphs and Fine and Gray competing risk regression analyses were used to study the association of age, race, comorbidity groupings, and tumor variables with 3 competing mortality outcomes: ...
Common variants in 94 loci have been associated with breast cancer including 15 loci with genome-wide significant associations (P,5 x 10(-8)) with oestrogen receptor (ER)-negative breast cancer and BRCA1-associated breast cancer risk. In this study, to identify new ER-negative susceptibility loci, we performed a meta-analysis of 11 genome-wide association studies (GWAS) consisting of 4,939 ER-negative cases and 14,352 controls, combined with 7,333 ER-negative cases and 42,468 controls and 15,252 BRCA1 mutation carriers genotyped on the iCOGS array. We identify four previously unidentified loci including two loci at 13q22 near KLF5, a 2p23.2 locus near WDR43 and a 2q33 locus near PPIL3 that display genome-wide significant associations with ER-negative breast cancer. In addition, 19 known breast cancer risk loci have genome-wide significant associations and 40 had moderate associations (P,0.05) with ER-negative disease. Using functional and eQTL studies we implicate TRMT61B and WDR43 at 2p23.2 and ...
Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy.s profile, publications, research topics, and co-authors
The Ets-1 transcription factor is a candidate breast cancer oncogene that regulates the expression of genes involved in tumor progression and metastasis. Ets-1 signaling has also been linked to the development of a basal-like breast cancer phenotype. We recently described a nitric oxide (NO)-induced gene signature that is associated with poor disease outcome in estrogen receptor-negative (ER-) breast cancer and contains both stem cell-like and basal-like components. Thus, we examined the role of Ets-1 in NO signaling and NO-induced phenotypes in ER- human breast cancer cells. Promoter region analyses were performed on genes upregulated in inducible nitric oxide synthase (NOS2) high expressing tumors for Ets-binding sites. In vitro mechanisms were examined in human basal-like breast cancer cells lines. NO signaling effects were studied using either forced NOS2 expression or the use of a chemical NO-donor, diethlylenetriamine NONOate (DETANO). Promoter region analysis of genes that are up-regulated in
Breast cancer management takes different approaches depending on physical and biological characteristics of the disease, as well as the age, over-all health and personal preferences of the patient. Treatment types can be classified into local therapy (surgery and radiotherapy) and systemic treatment (chemo-, endocrine, and targeted therapies). Local therapy is most efficacious in early stage breast cancer, while systemic therapy is generally justified in advanced and metastatic disease, or in diseases with specific phenotypes. Historically, breast cancer was treated with radical surgery alone. Advances in the understanding of the natural course of breast cancer as well as the development of systemic therapies allowed for the use of breast-conserving surgeries, however, the nomenclature of viewing non-surgical management from the viewpoint of the definitive surgery lends to two adjectives connected with treatment timelines: adjuvant (after surgery) and neoadjuvant (before surgery). The mainstay ...
Breast cancer is considered as a fatal disease and it is known to be the number one cause of cancer fatality in women. According to American cancer society, an estimated 1.3 million new breast cancer instances are detected every year which includes 465,000 deaths. In order to productively tackle this devastating disease, we must push innovative scientists to research cancer at its most basic stage. In other words, breast cancer research work should be done at its molecular stage. Also, besides the governments, private organizations must offer flexible budget to scientists who will be doing breast cancer research work.. Proper financial support of breast cancer investigation projects; can not only lead to better prevention methods but it can also assist towards earlier detection techniques and new anticancer drugs and cure.. Not so long ago, scientists who are working towards breast cancer research project, have created and successfully tested a breast cancer vaccine which is possibly to cure ...
Purpose: Mammographic density is one of the strongest risk factors for breast cancer. However, very little is known about how other breast cancer risk factors may modify the association between breast density and breast cancer. We investigated if associations of breast density and breast cancer differ according to the level of other known breast cancer risk factors.. Methods: This study included 1,044 incident breast cancer cases diagnosed within the Nurses Health Study cohort and 1,794 matched controls. Percent breast density, absolute dense and non-dense areas were measured from digitized film images with computer-assisted methods. Information on breast cancer risk factors was obtained prospectively from biennial questionnaires completed before the date of the cancer diagnosis for cancer cases and their matched controls. We used multivariate logistic regression to describe the association between breast density measures and breast cancer risk. The risk estimates were presented as odds ratios ...
TY - JOUR. T1 - External Validity of a Trial Comprised of Elderly Patients With Hormone Receptor-Positive Breast Cancer. AU - van de Water, Willemien. AU - Kiderlen, Mandy. AU - Bastiaannet, Esther. AU - Siesling, Sabine. AU - Westendorp, Rudi G.J.. AU - van de Velde, Cornelis J.H.. AU - Nortier, Johan W.R.. AU - Seynaeve, Caroline. AU - de Craen, Anton J.M.. AU - Liefers, Gerrit-Jan. PY - 2014. Y1 - 2014. N2 - Background: Inclusion in trials is selective, and thus results may not be generalizable to the general population. The aim of this study was to investigate the external validity of randomized clinical trial outcomes for elderly breast cancer patients.Methods: We compared characteristics and outcomes of breast cancer patients (n = 1325) who participated in a randomized clinical trial (Tamoxifen Exemestane Adjuvant Multinational trial) with unselected breast cancer patients of corresponding age from the general population (n = 1056). Dutch patients aged 65 years or older at diagnosis of ...
NBCC believes that research is the best weapon we have to end breast cancer and recognizes that the financial resources available to complete this task are not infinite. Therefore, it is critical that breast cancer research be as effective as possible. NBCC is dedicated to increasing the effectiveness of breast cancer research by collaborating with investigators and involving knowledgeable breast cancer advocates in all aspects of research design and oversight. NBCC has also made strides towards improving the effectiveness of breast cancer research by bringing together leading thinkers from many fields to create innovative research strategies and pioneer new research models. As a result of these experiences, NBCC has determined that certain values facilitate progress toward ending breast cancer.. Breast cancer research takes place within many disciplines, including, among others, basic science, clinical research, epidemiology, social sciences, and health services research. Generally, research ...
Breast cancer classification divides breast cancer into categories according to different schemes criteria and serving a different purpose. The major categories are the histopathological type, the grade of the tumor, the stage of the tumor, and the expression of proteins and genes. As knowledge of cancer cell biology develops these classifications are updated. The purpose of classification is to select the best treatment. The effectiveness of a specific treatment is demonstrated for a specific breast cancer (usually by randomized, controlled trials). That treatment may not be effective in a different breast cancer. Some breast cancers are aggressive and life-threatening, and must be treated with aggressive treatments that have major adverse effects. Other breast cancers are less aggressive and can be treated with less aggressive treatments, such as lumpectomy. Treatment algorithms rely on breast cancer classification to define specific subgroups that are each treated according to the best ...
Fertility and pregnancy issues are of key importance for young breast cancer patients. Despite several advances in the field, there are still multiple unmet needs and barriers in discussing and dealing with these concerns. To address the significant challenges related to fertility and pregnancy issues, the PREgnancy and FERtility (PREFER) study was developed as a national comprehensive program aiming to optimize care and improve knowledge around these topics. The PREFER study is a prospective cohort study conducted across several Italian institution affiliated with the Gruppo Italiano Mammella (GIM) group evaluating patterns of care and clinical outcomes of young breast cancer patients dealing with fertility and pregnancy issues. It is composed of two distinctive studies: PREFER-FERTILITY and PREFER-PREGNANCY. The PREFER-FERTILITY study is enrolling premenopausal patients aged 18-45 years, diagnosed with non-metastatic breast cancer, who are candidates to (neo)adjuvant chemotherapy and not previously
The Hormonal therapy resistant estrogen-receptor positive metastatic breast cancer cohort (HORSE-BC) study is a multicenter observational study evaluating the efficacy and safety of secondary endocrine therapy (ET) for postmenopausal cases of metastatic breast cancer (MBC) with poor response to primary ET. In this initial report we analyze the HORSE-BC baseline data to clarify the current status of treatment selection for MBC in Japan. Baseline data for the 50 patients enrolled in HORSE-BC were analyzed, including patient characteristics, types of secondary ET, and reasons for selecting secondary ET. Postoperative recurrence was detected in 84% of patients (42/50) and de novo stage IV breast cancer in 16% (8/50). Forty-one patients (41/50; 82%) received fulvestrant, 5 patients (10%) received selective estrogen receptor modulators (SERMs), 3 patients (6%) received ET plus a mammalian target of rapamycin (mTOR) inhibitor, and 1 patient received an aromatase inhibitor (AI) as the secondary ET. ...
Tongshu Capsule Down-Regulates the Expression of Estrogen Receptor α and Suppresses Human Breast Cancer Cell Proliferation. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
More than two million American women are breast cancer survivors. Approximately one-third of these women are premenopausal at diagnosis and face issues related to reproduction as they undergo cancer treatment. Ovarian function after breast cancer diagnosis has implications on breast cancer prognosis, choice of adjuvant therapy and reproductive issues such as desire for fertility or concerns about menopause. Therefore, tools to accurately predict ovarian function in breast cancer survivors could significantly impact physicians and patients in counseling, medical and surgical treatment choices, and consideration of fertility preservation options.. The goal of this proposal is to identify pre-chemotherapy hormonal, genetic and ovarian imaging markers that can predict ovarian failure and characterize the course of ovarian function after chemotherapy. The investigators plan to follow a group of young women from breast cancer diagnosis to five years after chemotherapy. The investigators will study the ...
Even luminal A tumors - normally considered the easiest breast cancer tumors for doctors to eradicate and for the patient to survive - can still cause death a decade after they are found through cancer marker lab testing.. These findings, appearing in the journal Cancer Epidemiology, Biomarkers and Prevention, were compiled over the course of 21 years of monitoring 1,000 breast cancer patients at Kaiser Permanente Southern California.. It is important to consider breast cancer molecular subtypes in determining the optimal treatment for women with breast cancer. Women with luminal A tumors - the least aggressive but most common cancerous breast tumor - could benefit from extended treatment, said Reina Haque, lead study author from the Kaiser Permanente Southern California Department of Research and Evaluation.. Nonetheless, breast cancer patients have a high likelihood of surviving luminal A tumors, compared to the four other types of breast cancer listed by the Kaiser researchers. The Centers ...
Kellie Martens, M.A., a doctoral student at the University of Colorado Denver, works with Dr. Kristin Kilbourn in the field of psycho-oncology. She is interested in learning what influences quality of life in young breast cancer survivors, with the intention of designing support groups or ways of screening that might make adjusting to a breast cancer diagnosis less difficult for young women. Please refer to the flyers (below) for more information. Its easy to participate, as women must only complete an on-line survey (IRB approved). ...
TY - JOUR. T1 - Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00. AU - Munzone, Elisabetta. AU - Gray, Kathryn P.. AU - Fumagalli, Caterina. AU - Guerini-Rocco, Elena. AU - Láng, István. AU - Ruhstaller, Thomas. AU - Gianni, Lorenzo. AU - Kammler, Roswitha. AU - Viale, Giuseppe. AU - Di Leo, Angelo. AU - Coates, Alan S.. AU - Gelber, Richard D.. AU - Regan, Meredith M.. AU - Goldhirsch, Aron. AU - Barberis, Massimo. AU - Colleoni, Marco. PY - 2018/7/1. Y1 - 2018/7/1. N2 - Purpose: We investigated the occurrence and the prognostic and predictive relationship of a selected number of somatic mutations in triple-negative breast cancer (TNBC) patients having known clinical outcomes treated within the IBCSG Trial 22-00. Methods: A matched case-control sampling selected patients enrolled in the IBCSG Trial 22-00 who had TNBC tumors, based on local assessment. Cases had invasive breast cancer recurrence (at local, regional, or ...
BioAssay record AID 103718 submitted by ChEMBL: In vitro cytotoxicity against human breast carcinoma cell line MCF-7 at 8.1*10e-5M.
A receptor blotting technique was used to detect SH2 domain containing epidermal growth factor receptor (EGFR) substrates that exhibited differential expression either between normal breast epithelial cells and breast cancer cells or between different human breast cancer cell lines. This identified a 25 kD protein, subsequently identified as Grb2, which was markedly overexpressed in three breast cancer cell lines (MCF-7, MDA-MB-361 and -453) relative to both normal breast epithelial cells and the majority of breast cancer cell lines. Northern blot analysis revealed that 7/19 breast cancer cell lines exhibited more than twofold overexpression of Grb2 mRNA, with overexpression correlating with high expression of erbB receptors. In MCF-7, MDA-MB-361 and -453 cells the overexpression of Grb2 mRNA and protein was accompanied by a small amplification of the Grb2 gene locus. Overexpression of Grb2 correlated with increased complex formation between Grb2 and the hSos-1 Ras GDP-GTP exchange protein. This
This textbook provides a comprehensive overview of the state of the art knowledge of breast cancer management for the modern breast surgeon. It covers all aspects of multidisciplinary care including primary breast and axillary surgery, reconstruction and oncoplastic techniques, external beam
Operable breast cancer patients may experience late recurrences because of reactivation of dormant tumor cells within the bone marrow (BM). Identification of patients who would benefit from extended therapy is therefore needed. BM samples obtained pre- and post-surgery were previously analysed for presence of disseminated tumor cells (DTC) by a multimarker mRNA quantitative reverse-transcription PCR assay. Updated survival analyses were performed on all patient data (n = 191) and in a subgroup of patients alive and recurrence-free after 5 years (n = 156). DTC data were compared to the mitotic activity index (MAI) of the primary tumors. Median follow-up time was 15.3 years. Among the 191 patients, 49 (25.65%) experienced systemic relapse, 24 (49%) within 5-18 years after surgery. MAI and pre- and post-operative DTC status had significant prognostic value based on Kaplan-Meier analyses and multiple Cox regression in the overall patient cohort. With exclusion of patients who relapsed or died within 5 years
We undertook this study to determine whether women with increased breast density had a greater likelihood of developing invasive breast cancer following lumpectomy for DCIS when compared to women with lower breast density, adjusting for age and radiation treatment. Our findings support the only previous report examining the association between breast density and DCIS recurrence, which suggested that the rate of second breast events following a diagnosis of DCIS may be increased in women with high breast density (33). In this previous study, breast density was measured as a continuous variable which was then categorized into four breast density groups. The number or events was comparable to the current study, with 91 ipsilateral events and 28 contralateral events. When compared with the lowest density group (,25% dense), the highest density group (≥75% dense) had an adjusted relative risk of 3.2 [95% confidence interval (95% CI), 1.2-8.5] for any invasive cancer. In comparison, although we ...
Additional breast cancers found with MRI are sometimes larger and potentially more aggressive than those found on mammography, and in some cases, may necessitate a change in treatment plan.
...Many breast cancer patients are treated with a drug called tamoxifen. ... Resistances to drugs are the main reason why therapies fail and disea...By treating breast cancer cells in vitro with regular doses of tamoxif...If microRNA 375 levels are low breast cancer cells increase the produ...,MicroRNA,controls,malignancy,and,resistance,of,breast,cancer,cells,biological,biology news articles,biology news today,latest biology news,current biology news,biology newsletters
TY - JOUR. T1 - Association analysis identifies 65 new breast cancer risk loci. AU - Michailidou, Kyriaki. AU - Lindström, Sara. AU - Dennis, Joe. AU - Beesley, Jonathan. AU - Hui, Shirley. AU - Kar, Siddhartha. AU - Lemaçon, Audrey. AU - Soucy, Penny. AU - Glubb, Dylan. AU - Rostamianfar, Asha. AU - Bolla, Manjeet K. AU - Wang, Qin. AU - Tyrer, Jonathan. AU - Dicks, Ed. AU - Lee, Andrew. AU - Wang, Zhaoming. AU - Allen, Jamie. AU - Keeman, Renske. AU - Eilber, Ursula. AU - French, Juliet D. AU - Qing Chen, Xiao. AU - Fachal, Laura. AU - McCue, Karen. AU - McCart Reed, Amy E. AU - Ghoussaini, Maya. AU - Carroll, Jason S. AU - Jiang, Xia. AU - Finucane, Hilary. AU - Adams, Marcia. AU - Adank, Muriel A. AU - Ahsan, Habibul. AU - Aittomäki, Kristiina. AU - Anton-Culver, Hoda. AU - Antonenkova, Natalia N. AU - Arndt, Volker. AU - Aronson, Kristan J. AU - Arun, Banu. AU - Auer, Paul L. AU - Bacot, François. AU - Barrdahl, Myrto. AU - Baynes, Caroline. AU - Beckmann, Matthias W. AU - Behrens, ...
TY - JOUR. T1 - Reclaiming life on ones own terms. T2 - A grounded theory study of the process of breast cancer survivorship. AU - Sherman, Deborah Witt. AU - Rosedale, Mary. AU - Haber, Judith. PY - 2012/5. Y1 - 2012/5. N2 - Purpose/Objectives: To develop a substantive theory of the process of breast cancer survivorship. Research Approach: Grounded theory. Setting: A LISTSERV announcement posted on the SHARE Web site and purposeful recruitment of women known to be diagnosed and treated for breast cancer. Participants: 15 women diagnosed with early-stage breast cancer. Methodologic Approach: Constant comparative analysis. Main Research Variables: Breast cancer survivorship. Findings: The core variable identified was Reclaiming Life on Ones Own Terms. The perceptions and experiences of the participants revealed overall that the diagnosis of breast cancer was a turning point in life and the stimulus for change. That was followed by the recognition of breast cancer as now being a part of life, ...
Dent et al 20 showed that patients with Triple negative breast cancer has less lymph node metastases but is more aggressively. It may be due to hematogenous spread or lack of targetable treatment. Chengshuai Si et al 21 study showed that tumor size and tumor subtype show statistical significance with LN involvement. Luminal B type showed significant higher probability of LN involvement, Triple positive and triple negative breast cancer accounts the most and least possibility of LN involvement.. Emi Yoshihara et alHYPERLINK https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589678/ l R3″22 study showed that the incidence of ALNM was significantly associated with the presence of LVI (P,0.001), larger tumour size (P , 0.001), higher histologic grade (P , 0.001) and no effect of age. Elsayed M Ali1 et al23study evaluated 258 patients with invasive breast carcinomas, ER and PR expression were demonstrated in 78.7% and 76.4%, respectively and over-expression of HER-2/neu was detected in 13.2% of ...
TAMPA, Fla. - Immunotherapy is a fast growing area of cancer research. It involves developing therapies that use a patients own immune system to fight and kill cancer. Moffitt Cancer Center is working on a new vaccine that would help early-stage breast cancer patients who have HER2 positive disease. The HER2 protein is overexpressed in nearly 25 percent of all breast cancer tumors and is associated with aggressive disease and poor prognosis. Moffitt researchers, led by physician-scientist Brian J. Czerniecki, M.D., Ph.D., have previously shown that immune cells are less able to recognize and target cancer cells that express HER2 as breast cancer progresses into a more advanced and invasive stage. This suggests that strategies that can restimulate the immune system to recognize and target HER2 early during cancer development may be effective treatment options.. The researcher team developed a vaccine that helps the immune system recognize the HER2 protein on breast cancer cells. Their approach ...
Health, ...A gene target for drug resistance a triple-drug cocktail for triple n...SIMPLE FINGERTIP TEST MAY IDENTIFY BREAST CANCER PATIENTS AT RISK FOR ...CTS most often associated with computer keyboard typing is caused by...For the study researchers gathered and analyzed information on 104 wo...,Simple,fingertip,test,may,identify,breast,cancer,patients,at,risk,for,carpal,tunnel,syndrome,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
Tamoxifen reduces recurrence risk among women treated for estrogen receptor-positive breast cancer. Its effectiveness partly depends on metabolic activation via cytochrome P450 2D6 (CYP2D6). Some medications compromise CYP2D6 activity and may lower plasma concentrations of active tamoxifen metabolites. We studied the association between concurrent use of tamoxifen and CYP2D6-inhibiting medications and breast cancer recurrence among Danish women diagnosed with early-stage, estrogen receptor-positive breast cancer. Using the Danish Breast Cancer Cooperative Group Registry, we identified 366 cases with local or distant breast cancer recurrence and 366 matched breast cancer controls. We ascertained concurrent prescription of CYP2D6-inhibiting medications during tamoxifen treatment by linking to the national prescription database covering all Danish pharmacies. We computed the breast cancer recurrence odds ratio (OR) and 95% confidence interval for each medication. The pooled recurrence OR was null ...
These new funds bring Susan G. Komens total breast cancer research investment to more than $1 billion since its inception in 1982, and investment in research focused on metastatic breast cancer to $210 million. Next to the U.S. government, Susan G. Komen is the largest nonprofit funder of breast cancer research in the world, and much of that investment has been awarded to scientists and research institutions in San Diego. As a local office, Susan G. Komen San Diego has invested more than $19 million in global breast cancer research and local breast health services since our inception in 1995.. In order to save more lives, we must address the main cause of breast cancer deaths: metastatic breast cancer, said George Sledge, Susan G. Komens Chief Scientific Advisor, M.D., Professor of Medicine, and Chief of the Division of Oncology in the Department of Medicine at Stanford University.. Metastatic (stage iv) breast cancer is the most advanced stage of breast cancer, which does not yet have a ...
Ductal means that the cancer starts inside the milk ducts, carcinoma refers to any cancer that begins in the skin or other tissues including breast tissue that cover or line the internal organs, and in situ means in its original place. When you have had DCIS, you are at higher risk for the cancer coming back or for developing a new breast cancer than a person who has never had breast cancer before.. Most recurrences happen within the 5 to 10 years after initial diagnosis. Learn what additional steps you can take to lower your risk of a new breast cancer diagnosis or a recurrence in the Lower Your Risk section. If breast cancer does come back after earlier DCIS treatment, the recurrence is non-invasive DCIS again about half the time and invasive about half the time.. According to the American Cancer Society, about 60, cases of DCIS are diagnosed in the United States each year, accounting for about 1 out of every 5 new breast cancer cases. There are two main reasons this number is so large and ...
Ductal means that the cancer starts inside the milk ducts, carcinoma refers to any cancer that begins in the skin or other tissues including breast tissue that cover or line the internal organs, and in situ means in its original place.. When you have had DCIS, you are at higher risk for the cancer coming back or for developing a new breast cancer than a person who has never had breast cancer before. Most recurrences happen within the 5 to 10 years after initial diagnosis. Learn what additional steps you can take to lower your risk of a new breast cancer diagnosis or a recurrence in the Lower Your Risk section.. If breast cancer does come back after earlier DCIS treatment, the recurrence is non-invasive DCIS again about half the time and invasive about half the time. According to the American Cancer Society, about 60, cases of DCIS are diagnosed in the United States each year, accounting for about 1 out of every 5 new breast cancer cases.. There are two main reasons this number is so large and ...
Background The aim of this retrospective study was to determine whether progesteron receptor (PgR) status have an influence on the prognosis of estrogen receptor positive (ER+)/HER2-negative breast carcinoma (BC).. Methods We retrospectively reviewed the medical files of 1680 operable BC patients (pts) diagnosed between 1996 and 2011 and 456 of whom ER,PgR and HER2 status known were included in this study. Patients were categorized into 2 groups; as group A (ER + /PgR-/HER2-negative) and group B (ER + /PgR + /HER2-negative). Twenty one percent (97 pts) of the pts were in group A.. Results Median follow up was 33.5 (0-177) months. Median age was 54 (21-90) years. Sixty-one percent (278) of the pts had node-positive BC. Sixty percent (276) of the pts were postmenopausal. Eighty percent (365) of the pts received adjuvant chemotherapy (ACT). Adjuvant hormonotherapy (AHT) was recommended to nearly all patients (mostly tamoxifen). Pts in group A had significantly higher lymph node positive disease as ...
Triple-negative (TN) breast cancer is an aggressive subtype of breast cancer associated with a unique set of epidemiologic and genetic risk factors. We conducted a two-stage genome-wide association study of TN breast cancer (stage 1: 1529 TN cases, 3399 controls; stage 2: 2148 cases, 1309 controls) to identify loci that influence TN breast cancer risk. Variants in the 19p13.1 and PTHLH loci showed genome-wide significant associations (P , 5 × 10(-) (8)) in stage 1 and 2 combined. Results also suggested a substantial enrichment of significantly associated variants among the single nucleotide polymorphisms (SNPs) analyzed in stage 2. Variants from 25 of 74 known breast cancer susceptibility loci were also associated with risk of TN breast cancer (P , 0.05). Associations with TN breast cancer were confirmed for 10 loci (LGR6, MDM4, CASP8, 2q35, 2p24.1, TERT-rs10069690, ESR1, TOX3, 19p13.1, RALY), and we identified associations with TN breast cancer for 15 additional breast cancer loci (P , 0.05: ...
BACKGROUND: Adjuvant trastuzumab has been routinely used in HER2-positive operable breast cancer patients. Prognostic factors remain to be well characterized in these patients and might correlate with primary and/or acquired resistance to trastuzumab.. PATIENTS AND METHODS: The study subjects were 78 HER2-positive operable breast cancer patients treated with adjuvant chemotherapy followed by 1-year trastuzumab between 2005 and 2010 in our institute. All breast tumors showed a HercepTest score of 3+ or that of 2+ and positive fluorescence in situ hybridization. Expression levels of HER1, phosphorylated HER2 (pY1248), HER3, HER4, and p53 were assessed by immunohistochemistry. Prognostic factors were investigated with univariate and multivariate analyses using the Kaplan-Meier/log-rank test and Cox proportional hazards model, respectively.. RESULTS: The median age and follow-up period of the patients were 54 years and 39 months, respectively. The mean tumor size was 2.1 cm and the node-positive ...
Physical activity after breast cancer diagnosis has been linked with prolonged survival and improved quality of life, but most participants in a large breast cancer study did not meet national physical activity guidelines after they were diagnosed. Moreover, African-American women were less likely to meet the guidelines than were White women.. Published online in Cancer, a peer-reviewed journal of the American Cancer Society, the findings indicate that efforts to promote physical activity in breast cancer patients may need to be significantly enhanced.. The study, Racial differences in physical activity among breast cancer survivors: implications for breast cancer care, was led by Ms. Brionna Hair, epidemiology doctoral student at the University of North Carolina Gillings School of Global Public Health.. The U.S. Department of Health and Human Services and the American Cancer Society recommend that adults engage weekly in at least 150 minutes of moderate-intensity physical activity or 75 ...
Introduction: Identification of gene expression-based breast cancer subtypes is considered a critical means of prognostication. Genetic mutations along with epigenetic alterations contribute to gene-expression changes occurring in breast cancer. So far, these epigenetic contributions to sporadic breast cancer subtypes have not been well characterized, and only a limited understanding exists of the epigenetic mechanisms affected in those particular breast cancer subtypes. The present study was undertaken to dissect the breast cancer methylome and to deliver specific epigenotypes associated with particular breast cancer subtypes. Methods: By using a microarray approach, we analyzed DNA methylation in regulatory regions of 806 cancer-related genes in 28 breast cancer paired samples. We subsequently performed substantial technical and biologic validation by pyrosequencing, investigating the top qualifying 19 CpG regions in independent cohorts encompassing 47 basal-like, 44 ERBB2+ overexpressing, 48 ...
Background: We aimed to estimate the effect of alcohol consumption on breast cancer risk and to test whether overweight and obesity modifies this association. Methods: We included in the analysis 45,233 women enrolled in the Swedish Womens Lifestyle and Health study between 1991 and 1992. Participants were followed for occurrence of breast cancer and death until December 2009. Poisson regression models were used, and analyses were done for overall breast cancer and for estrogen receptor positive or negative (ER+, ER-) and progesterone receptor positive and negative (PR+, PR-) tumors separately. Results: A total of 1,385 breast cancer cases were ascertained during the follow-up period. Overall, we found no statistically significant association between alcohol intake and breast cancer risk after adjustment for confounding, with an estimated relative risk (RR) of 1.01 (95 % CI: 0.98-1.04) for an increment in alcohol consumption of 5 g/day. A statistically significant elevated breast cancer risk ...
The authors retrospectively examined the contralateral prophylactic mastectomy (CPM) rate among 100 women with ductal carcinoma in situ who are BRCA negative. Of 100 women with ductal carcinoma in situ, 31 elected contralateral prophylactic mastectomy (CPM). Factors associated with increased likelihood of undergoing contralateral prophylactic mastectomy (CPM) among this cohort were: family history of ovarian cancer, marital status, reconstruction, mastectomy of the affected breast, and tamoxifen use.. Keywords: contralateral prophylactic mastectomy, BRCA negative ...
Scientists at the British Columbia Cancer Agency and University of British Columbia have identified new breast cancer genes. This is a discovery that may change the way breast cancer is diagnosed, as well the way it is treated. - Identification of New Breast Cancer Genes - Breast Cancer at BellaOnline
TY - JOUR. T1 - Longitudinal MRI Evaluation of Intracranial Development and Vascular Characteristics of Breast Cancer Brain Metastases in a Mouse Model. AU - Zhou, Heling. AU - Chen, Min. AU - Zhao, Dawen. PY - 2013/4/29. Y1 - 2013/4/29. N2 - Longitudinal MRI was applied to monitor intracranial initiation and development of brain metastases and assess tumor vascular volume and permeability in a mouse model of breast cancer brain metastases. Using a 9.4T system, high resolution anatomic MRI and dynamic susceptibility contrast (DSC) perfusion MRI were acquired at different time points after an intracardiac injection of brain-tropic breast cancer MDA-MB231BR-EGFP cells. Three weeks post injection, multifocal brain metastases were first observed with hyperintensity on T2-weighted images, but isointensity on T1-weighted post contrast images, indicating that blood-tumor-barrier (BTB) at early stage of brain metastases was impermeable. Follow-up MRI revealed intracranial tumor growth and increased ...
Contralateral prophylactic mastectomy: current perspectives Katharine Yao,1 Mark Sisco,2 Isabelle Bedrosian3 1Division of Surgical Oncology, Department of Surgery, 2Division of Plastic Surgery, Department of Surgery, NorthShore University HealthSystem, Evanston, IL, 3Department of Surgery, MD Anderson Cancer Center, Houston, TX, USA Abstract: There has been an increasing trend in the use of contralateral prophylactic mastectomy (CPM) in the United States among women diagnosed with unilateral breast cancer, particularly young women. Approximately one-third of women ,40 years old are undergoing CPM in the US. Most studies have shown that the CPM trend is mainly patient-driven, which reflects a changing environment for newly diagnosed breast cancer patients. The most common reason that women choose CPM is based on misperceptions about CPM’s effect on survival and overestimation of their contralateral breast cancer (CBC) risk. No prospective studies have shown survival benefit to CPM, and
The practice of contralateral prophylactic mastectomy (CPM) has increased in woman with unilateral breast cancer. This highly invasive approach to the management of breast cancer has been done without hard evidence that it conveys a survival benefit. Survival Outcomes After Contralateral Prophylactic Mastectomy: A Decision Analysis by Pamela R. Portschy, Karen M. Kuntz, and Todd M. Tuttle just published in the Journal of the National Cancer Institute examines survival outcomes in women with and without CPM. The study excluded women with BRCA mutations. These mutations greatly increase the risk of getting breast, ovarian, and other cancers.. Women choose to have this procedure because of the fear of getting the disease in the remaining breast, though this likelihood is much less common than most patients suppose. Obviously this treatment is only performed on patients who have already had a mastectomy. If the cancer had been treated with any modality short of mastectomy CPM would not be a ...
Background: Metastasis is important in survival and the quality of life of female breast cancer patients. This study was run in order to investigate metastasis and its related factors in female breast cancer patients in Kerman province from 2005 to 2015. The aim of this study was to investigate the factors associated with secondary metastasis in female breast cancer patients in the largest province of Iran (Kerman). Materials and Methods: In this case-control study, medical records of women diagnosed with breast cancer between the years of 2005 to 2015 were studied. Among them, 200 breast cancer patients with secondary metastasis were randomly selected as cases and 400 patients without metastasis were selected as the control group. Backward logistic regression, chi-square test, t-test and Mann-Whitney-U test were performed for comparing the two groups in SPSS 22. Results: Disease stage at diagnosis was significantly associated with secondary metastasis (p|0.001). Female patients with stage III breast
Triple negative breast cancers are defined by the lack of targeted therapy available for women with this type of breast cancer. Where women with hormone positive breast cancers can benefit from hormone therapies, like tamoxifen and aromatase inhibitors, and HER2+ breast cancers benefit from targeted therapies like Herceptin and Bevacizumab, treatment for triple negative breast cancers are limited to the slash/burn/poison of surgery/radiation/chemotherapy. Where once women with HER2+ breast cancers were considered to have the worst outcomes since the development of targeted HER2 therapies, the terrible distinction of worst outcomes of breast cancer subtypes now goes to triple negative disease. Here are some updates on triple negative disease from this years San Antonio Breast Cancer Symposium.. Carboplatin. Two trials reported on Wednesday afternoon looked at carboplatin to treat triple negative breast cancer. Prior data has not established a role for this highly toxic treatment in early stage ...
A recent study reporting the absolute 20-year survival benefit from contralateral prophylactic mastectomy was less than 1% for women with stage I and II breast cancer without BRCA mutations runs counter to common perceptions about the risk of contralateral breast cancer among these women and the benefits of contralateral prophylactic mastectomy.1 (Earlier studies about perceptions of contralateral breast cancer and contralateral prophylactic mastectomy are referenced in the current study.). The less than 1% survival benefit was found among all subgroups studied-by age, estrogen receptor status, and cancer stage-although contralateral prophylactic mastectomy was more beneficial among younger women, those with stage I disease, and those with estrogen receptor-negative breast cancer, according to the report, published in the Journal of the National Cancer Institute.1 The stated aim of the study was to provide projected long-term survival information by using a stimulated Markov model for ...
Gentaur molecular products has all kinds of products like :search , US Biomax \ Breast invasive ductal carcinoma tissue array with matched adjacent normal breast tissue, including TNM and pathology grade, 6 cases_24 cores, replacing BR243 \ BR243a for more molecular products just contact us
Gentaur molecular products has all kinds of products like :search , US Biomax \ Breast invasive ductal carcinoma with matched or unmatched adjacent normal breast tissue array, including TNM and pathology grade, 47cases_80cores, replacing BR802 \ BR802b for more molecular products just contact us
SAN DIEGO, Dec. 7, 2017 /PRNewswire/ - Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced that preclinical data demonstrating the sensitivity of triple negative breast cancer (TNBC) cell lines to PCM-075, its highly selective Polo-like kinase 1 (PLK1) Inhibitor, will be featured as a Poster Presentation at the 40th San Antonio Breast Cancer Symposium (SABCS) on December 7th, from 5:00 - 7:00 PM CST, in San Antonio, Texas.. Trovagenes poster entitled, Sensitivity of Triple Negative Breast Cancer Cell Lines to PCM-075, a Highly Selective Polo-like Kinase 1 Inhibitor, presents the preclinical analysis of 40 cancer cell lines and demonstrates that triple negative breast cancer (TNBC) cell lines are 20-fold more sensitive to PCM-075 than estrogen receptor positive (ER+) breast cancer cells lines.. Polo-like Kinase 1 (PLK1) is known to be over-expressed in many hematologic and solid tumor cancers, including breast cancer. PLK1 inhibition by PCM-075 induces ...
Abstract: Increasing numbers of women with breast cancer are electing for contralateral prophylactic mastectomy (CPM) to reduce the risk of developing contralateral breast cancer. The objective of this study was to identify factors that may affect a patients decision to undergo CPM. We identified 2,504 women with stage 0 to III unilateral primary breast cancer who underwent breast surgery at our institution from January 2000 to August 2006 from a prospectively maintained database. We did logistic regression analyses to determine which factors were associated with undergoing CPM. Of 2,504 breast cancer patients, 1,223 (48.8%) underwent total mastectomy. Of the 1,223 patients who underwent mastectomy, 284 (23.2%) underwent immediate or delayed CPM. There were 33 patients (1.3%) who had genetic testing before the surgery, with the use of testing increasing in the latter years of the study (0.1% in 2000-2002 versus 2.0% in 2003-2006; P , 0.0001). Multivariable analysis revealed several factors that ...
Breast cancer is the most common form of cancer and the second leading cause of malignancy-associated death in women worldwide. Estrogens are the main sex hormones in women. They are essential for the development and function of normal breast mammary glands; however, prolonged exposure to estrogens increases the risk of breast cancer development and progression. Approximately two-thirds of all breast cancer patients are positive for estrogen receptor (ER), but only 50% of those cases can benefit from antiestrogen therapy.. In this thesis we investigated the effects of estrogen, diet modification, and anti-estrogen drugs on several immune modulators in normal human breast tissue. We used the microdialysis technique to sample the immune modulators in situ in normal human breast tissue, in malignant breast tissue, and in tumor tissue from both the immune competent mice with murine breast cancer and immune deficient mice bearing human breast tumors. Furthermore, we also used ex vivo culture of ...
Overexpression of the oncogene HER2/neu (c-erbB-2) occurs in up to 30% of breast cancers and is correlated with reduced survival, especially in node-positive disease. The aim of this study was to identify genes associated with the aggressive phenotype of HER2/neu-positive breast cancer cells using cDNA microarrays. RNA was extracted from three HER2/neu-positive and three HER2/neu-negative breast cancer cell lines. Pooled RNA was hybridized in duplicate to the breast specific microarray filters from Research Genetics containing 5184 unique cDNAs. Subsequently, a similar comparison was performed for pooled RNAs from 10 node-positive, ER-positive invasive ductal carcinomas, half of which were HER2/neu overexpressers. In HER2/neu overexpressing breast cancer cell lines, 90 (1.7%) genes were up-regulated and 46 (0.9%) were down-regulated, compared to cell lines with low HER2/neu protein levels. In contrast, in HER2/neu overexpressing primary breast cancers, more genes were down-regulated (N = 132, 2.5%) than
TY - JOUR. T1 - Unusual roles of caspase-8 in triple-negative breast cancer cell line MDA-MB-231. AU - De Blasio, Anna. AU - Di Fiore, Riccardo. AU - Morreale, Marco. AU - Carlisi, Daniela. AU - Drago-Ferrante, Rosa. AU - Montalbano, Mauro. AU - Scerri, Christian. AU - Tesoriere, Giovanni. AU - Vento, Renza. PY - 2016/1/1. Y1 - 2016/1/1. N2 - Triple-negative breast cancer (TNBC) is a clinically aggressive form of breast cancer that is unresponsive to endocrine agents or trastuzumab. TNBC accounts for ∼10-20% of all breast cancer cases and represents the form with the poorest prognosis. Patients with TNBC are at higher risk of early recurrence, mainly in the lungs, brain and soft tissue, therefore, there is an urgent need for new therapies. The present study was carried out in MDA-MB-231 cells, where we assessed the role of caspase-8 (casp-8), a critical effector of death receptors, also involved in non-apoptotic functions. Analysis of casp-8 mRNA and protein levels indicated that they were ...
Pregnancy is safe for women with estrogen receptor positive breast cancerSome people have basic questions about how pregnancy happens. Some may have questions about avoiding a pregnancy
Breast cancer brain metastases (BCBM) develop in about 20-30% of breast cancer (BC) patients. BCBM are associated with dismal prognosis not at least due to lack of valuable molecular therapeutic targets. The aim of the study was to identify new molecular biomarkers and targets in BCBM by using complementary state-of-the-art techniques. We compared array expression profiles of three BCBM with 16 non-brain metastatic BC and 16 primary brain tumors (prBT) using a false discovery rate (FDR) p | 0.05 and fold change (FC) | 2. Biofunctional analysis was conducted on the differentially expressed probe sets. High-density arrays were employed to detect copy number variations (CNVs) and whole exome sequencing (WES) with paired-end reads of 150 bp was utilized to detect gene mutations in the three BCBM. The top 370 probe sets that were differentially expressed between BCBM and both BC and prBT were in the majority comparably overexpressed in BCBM and included, e.g. the coding genes BCL3, BNIP3, BNIP3P1, BRIP1,
TY - JOUR. T1 - Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab. T2 - A multicenter retrospective observational study (JBCRG-C03 study). AU - Takada, M.. AU - Ishiguro, H.. AU - Nagai, S.. AU - Ohtani, S.. AU - Kawabata, H.. AU - Yanagita, Y.. AU - Hozumi, Y.. AU - Shimizu, C.. AU - Takao, S.. AU - Sato, N.. AU - Kosaka, Y.. AU - Sagara, Y.. AU - Iwata, H.. AU - Ohno, S.. AU - Kuroi, K.. AU - Masuda, N.. AU - Yamashiro, H.. AU - Sugimoto, M.. AU - Kondo, M.. AU - Naito, Yasuhiro. AU - Sasano, H.. AU - Inamoto, T.. AU - Morita, S.. AU - Toi, M.. PY - 2014. Y1 - 2014. N2 - We investigated the disease-free survival (DFS) of HER2-positive primary breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab, as well as predictive factors for DFS and pathologic response. Data from 829 female patients treated between 2001 and 2010 were collected from 38 institutions in Japan. Predictive factors were evaluated using ...
Circulating tumor cells (CTCs) are tumor cells shed from either primary tumors or its metastases that circulate in the peripheral blood of patients with metastatic cancers. The molecular characterization of the CTCs is critical to identifying the key drivers of cancer metastasis and devising therapeutic approaches. However, the molecular characterization of CTCs is difficult to achieve because their isolation is a major technological challenge. CTCs from two triple negative breast cancer patients were enriched using CellSearch and single cells selected by DEPArray™. A TP53 R110 fs*13 mutation identified by next generation sequencing in the breast and chest skin biopsies of both patients was studied in single CTCs. From 6 single CTC isolated from one patient, 1 CTC had TP53 R110 delC, 1 CTC showed the TP53 R110 delG mutation, and the remaining 4 single CTCs showed the wild type p53 sequence; a pool of 14 CTCs isolated from the same patient also showed TP53 R110 delC mutation. In the tumor breast tissue
Purpose: Breast conservation has been shown to have similar mortality rates as compared to mastectomy. We hypothesized that variables involving the patient, tumor and surgeon influence the treatment a patient may choose. Methods: Retrospective review of a prospectively maintained database of all patients who underwent surgical treatment for breast cancer between 2000 and 2009 was performed. Multivariate logistic regression models were used to compare characteristics associated with breast conservation therapy (BCT) and contralateral prophylactic mastectomy (CPM). Results: Of 1826 patients, 806 underwent BCT and 207 underwent CPM. Exclusion criteria included unilateral mastectomy (n = 761), bilateral disease, stage IV disease, and incomplete records. Larger average tumor size and number of lymph nodes examined were associated with CPM (both p | 0.0001). There were higher odds of patients who underwent CPM when younger than 40 (OR = 3.1), less than 50 years of age (OR = 2.5), with a history of breast
Estrogen receptor-negative (ER(-)) breast cancers have limited treatment options and are associated with earlier relapses. Because glucocorticoid receptor (GR) signaling initiates antiapoptotic pathways in ER(-) breast cancer cells, we hypothesized that activation of these pathways might be associated with poor prognosis in ER(-) disease. Here we report findings from a genome-wide study of GR transcriptional targets in a premalignant ER(-) cell line model of early breast cancer (MCF10A-Myc) and in primary early-stage ER(-) human tumors. Chromatin immunoprecipitation with massively parallel sequencing (ChIP-seq) coupled to time-course expression profiling led us to identify epithelial-to-mesenchymal transition (EMT) pathways as an important aspect associated with GR activation. We validated these findings by carrying out a meta-analysis of primary breast tumor gene expression from 1,378 early-stage breast cancer patients with long-term clinical follow-up, confirming that high levels of GR expression
Triple negative breasts cancer (TNBC) gets the poorest prognosis of most types of breasts malignancy and currently lacks effective targeted therapy. for TNBC treatment. Intro Triple negative breasts cancer (TNBC) makes up about ~15C20% of breasts cancer occurrence [1]. These tumors are extremely aggressive, metastatic, and also have the most severe short-term prognosis among all breasts malignancy types [1,2]. Unlike estrogen receptor positive (ER+) breasts cancer, which may be successfully treated with aromatase inhibitors, tamoxifen or various other selective estrogen receptor modulators (SERMs), there is absolutely no targeted therapy presently accepted for TNBC. Chemotherapy and medical procedures will be the current standard-of-care (SOC) for TNBC [1,3,4]. Aside from the severe unwanted effects connected with chemotherapies, the choice pressure induced by non-specific chemotherapy drugs as well as the advancement of drug level of resistance also can promote metastasis [5C8]. Surgery of the ...
Specific, high affinity receptors for 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] have been demonstrated in human breast cancer cells. In addition, 1,25-(OH)2D3 has been shown to inhibit replication in some human breast cancer cell lines, although the mechanism(s) of this anti-tumor activity remain undefined. There is currently considerable interest in the role of autocrine growth factors in the control of breast cancer cell proliferation and the effects of steroid hormones on their production, receptor binding, and action. Since the epidermal growth factor (EGF) receptor mediates the effects of both EGF and the autocrine growth factor, alpha-transforming growth factor, we investigated the effect of 1,25-(OH)2D3 on EGF receptor levels in several human breast cancer cell lines. Preincubation of T-47D cells with 1,25-(OH)2D3 for 24 h resulted in a significant concentration-dependent decline in the specific binding of [125I]EGF. The effect was observed when EGF binding was assayed at either 0 or 37 degrees C,
Estrogen receptor and progesterone receptor status are routinely assessed using immunohistochemistry assays to assist in patient prognosis and clinical management. Three commonly utilized autostainer vendors-Dako, Leica and Ventana-provide ready-to-use progesterone receptor assays; however, they have never been directly compared in a single breast cancer cohort. We looked at three immunohistochemical progesterone receptor assays, in addition to original ligand-binding assay results, in a single retrospective, tamoxifen-treated breast cancer cohort to investigate inter- and intra-observer agreement, concordance, prognostic ability and measures of test performance. All immunohistochemical assays utilized the manufacturers specified protocols. Five-year disease-free survival was the endpoint of interest, and multivariate models were adjusted for lymph node status, tumor grade, tumor size and human epidermal growth factor 2 status. All assays showed substantial to almost perfect agreement between the three
TY - JOUR. T1 - Risk of type 2 diabetes mellitus in female breast cancer patients treated with morphine. T2 - A retrospective population-based time-dependent cohort study. AU - Yang, Szu Pang. AU - Muo, Chih Hsin. AU - Wang, I. Kuan. AU - Chang, Yen Jung. AU - Lai, Shih Wei. AU - Lee, Cynthia Wei Sheng. AU - Morisky, Donald E.. PY - 2015/12/1. Y1 - 2015/12/1. N2 - Aims: We aimed to examine whether morphine treatment is associated with type 2 diabetes mellitus (T2DM) in female breast cancer patients. Methods: We conducted a retrospective cohort analysis of the Longitudinal Health Insurance Database for Catastrophic Illness Patients in Taiwan. A total of 31,112 women with breast cancer without T2DM history during the period 2000-2005 were identified, divided into morphine and non-morphine users (8071 and 23,041 patients, respectively), and the hazard ratios of newly diagnosed T2DM during the period 2005-2010 were calculated. We used a Cox proportional hazard model with time-dependent exposure ...
Objective To evaluate the value of mammographic findings at predicting the presence of an extensive intraductal component (EIC), a major factor in determining breast conserving surgery Methods A prospective study of 348 consecutive mammograms in patients with stage Ⅰ or Ⅱ breast carcinoma, including infiltrating ductal carcinoma ( n =297), ductal carcinoma in situ (DCIS) associated with small invasive foci ( n =8), mucinous carcinoma ( n =21), and medullary carcinoma ( n =22), was performed to determine the predictive value of mammographic features in evaluating the presence or absence of an EIC Results (1) EIC+ cancers were significantly more likely to show the lesion with microcalcifications in comparing with EIC- cases (66 4% vs 20 4%, χ 2=75 29, P 0 001) In particular, the presence of microcalcifications alone was more common for EIC+ cancers than for EIC- cancers (21 1% vs 2 0%, χ 2=52 56, P 0 001) (2) 54 6% of patients in whom mammograms showed only a
AND MATERIALS: From July 1986 to April 1993 the International Breast Cancer Study Group (IBCSG) Trial VI randomly assigned 1554 pre/perimenopausal node-positive breast cancer patients to receive cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) for either three consecutive courses on months 1-3, or six consecutive courses on months 1-6, both with or without reintroduction CMF. IBCSG Trial VII randomly assigned 1266 postmenopausal node-positive breast cancer patients to receive tamoxifen for 5 years, or tamoxifen for 5 years with three early cycles of CMF, both with or without three courses of delayed CMF. Both trials allowed a choice of mastectomy, or breast-conserving surgery plus radiation therapy, and both were stratified by type of surgery. Radiotherapy was delayed until the initial block of CMF was completed; 4 or 7 months after surgery for pre/perimenopausal patients, and 2 or 4 months after surgery for postmenopausal patients. Over both trials, 718 eligible patients elected to ...
TY - JOUR. T1 - I do not even say it - A mixed methods study on breast cancer awareness of omani women. AU - Alkhasawneh, Esra. AU - Siddiqui, Saad T.. AU - Leocadio, Michael. AU - Seshan, Vidya. AU - Al-Farsi, Yahya. AU - Al-Moundhri, Mansour S.. PY - 2016. Y1 - 2016. N2 - Background: The incidence of breast cancer is rising in Oman, and the disease is diagnosed at late stages, when treatment success is limited. Omani women might benefit from better awareness, so that breast cancer can be detected early and treated. This study was conducted to assess Omani womens levels of breast cancer awareness and early detection practice, and explore factors which might influence these levels. Materials and Methods: A mixed methods study was conducted in 2014, including a quantitative survey of 1,372 and a qualitative assessment of 19 Omani women, aged ≥20 years from five Omani governorates using convenient sampling. Demographic information and scores for awareness levels were used in a multivariate ...
Antiestrogens are currently used for treating breast cancer patients who have estrogen receptor-positive tumors. However, patients with advanced disease will eventually develop resistance to the drugs. Therefore, compounds effective on antiestrogen-resistant tumors will be of great importance for future breast cancer treatment. In this study, we have investigated the effect of the chemotherapeutic compound cisplatin using a panel of antiestrogen-resistant breast cancer cell lines established from the human breast cancer cell line MCF-7. We show that the antiestrogen-resistant cells are significantly more sensitive to cisplatin-induced cell death than antiestrogen-sensitive MCF-7 cells and we show that cisplatin induces cell death by activating both the caspase and lysosomal death pathways. The antiestrogen-resistant cell lines express lower levels of antiapoptotic Bcl-2 protein compared with parental MCF-7 cells. Our data show that Bcl-2 can protect antiestrogen-resistant breast cancer cells from
There is accumulating evidence to suggest that different histological grades of invasive ductal breast carcinomas may have distinct molecular origins and pathogenesis and do not typically progress from one grade group to another (28, 29, 30, 31) . The different grades have different clinical behaviors, and within-grade studies to identify the more aggressive subgroups of these classes of breast tumors would be of great assistance in clinical management. The expression of basal/myoepithelial markers has been observed in a proportion of grade III invasive breast tumors, and the spectrum of basal-like tumors, also recognized by morphology (15 , 32) , molecular cytogenetics (16 , 33) , and expression profiling (18 , 19) , has been associated with poor prognosis (17) . CGH has the advantage of being applied to archival pathology specimens with long-term follow-up as well as being amenable to microdissection strategies to profile the molecular genetic change occurring in a pure population of tumor ...
Single-agent poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) have been approved as the first targeted therapy available for patients with BRCA-mutated HER2-negative metastatic breast cancer. This meta-analysis aimed to better evaluate activity, efficacy and safety of single-agent PARPi in this population. A systematic search of Medline, Embase and conference proceedings up to 31 January 2018 was conducted to identify randomised controlled trials (RCTs) investigating single-agent PARPi versus monochemotherapy in patients with BRCA-mutated HER2-negative metastatic breast cancer. Using the random-effect model, we calculated summary risk estimates (pooled HR and OR with 95% CI) for progression-free survival (PFS), overall survival (OS), objective response rate (ORR), any grade and grade 3-4 adverse events (AEs), treatment discontinuation rate and time to deterioration in quality of life (QoL). Two RCTs (n=733) were included. As compared with monochemotherapy, single-agent PARPi significantly ...
New life-saving treatments for HER-2 Negative Metastatic Breast Cancer in clinical trial on Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer
New life-saving treatments for HER-2 Negative Metastatic Breast Cancer in clinical trial on Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer
Jin, R.,Bay, B.H.,Chow, V.T.K.,Tan, P.H.,Lin, V.C.L. (2000). Metallothionein 1E mRNA is highly expressed in oestrogen receptor-negative human invasive ductal breast cancer. British Journal of Cancer 83 (3) : 319-323. S[email protected] Repository ...
Background In early breast cancer, variations in local treatment that substantially affect the risk of locoregional recurrence could also affect long-term breast cancer mortality. To examine this relationship, collaborative metaanalyses were undertaken, based on individual patient data, of the relevant randomised trials that began by 1995. Methods Information was available on 42 000 women in 78 randomised treatment comparisons (radiotherapy vs no radiotherapy, 23 500; more vs less surgery, 9300; more surgery vs radiotherapy, 9300). 24 types of local treatment comparison were identified. To help relate the effect on local (ie, locoregional) recurrence to that on breast cancer mortality, these were grouped according to whether or not the 5-year local recurrence risk exceeded 10% (?10%, 17 000 women; ?10%, 25 000 women). Findings About three-quarters of the eventual local recurrence risk occurred during the first 5 years. In the comparisons that involved little (?10%) difference in 5-year local recurrence
Cisplatin (Csp) is a recurrently used chemotherapeutic drug but its use is inadequate due to undesirable adverse effects. In search of alternative medicine more attention has been given to phytochemicals. Septilin (Spt), a polyherbal drug and its therapeutic potential is huge but there is a scarcity of studies on its cytotoxic potential on cancer cells. The current study was designed to examine the effects of Spt in combination with Csp on human breast adenocarcinoma (MCF-7) and normal human breast epithelial (MCF-10A) cell lines. Cell viability for Spt treated cells was studied using MTT assay. IC50 value of Csp on MCF-7 cells was found to be 10 µg/mL at 24 h. This dose was further used to study the combined effects of Csp with Spt on MCF-7 and MCF-10A cell lines. Maximum cytotoxicity of Spt on MCF-7 cells was observed at Spt 5 µg/mL. The mechanism of Spt induced cytotoxicity was studied using apoptosis assay. Spt did not show any cytotoxic effects on MCF-10 A normal human breast epithelial ...
Researchers have found a biomarker that appears active in the growth and spread of triple-negative breast cancer. Known as interleukin-13 receptor alpha 2 (IL13Ralpha2), the biomarker may help doctors identify patients at high risk of disease spread and potentially provide a target for treatment. These findings were reported in Breast Cancer Research.. The majority of breast cancers are hormone receptor-positive, meaning that the cancer cells are stimulated to grow from exposure to the female hormones estrogen and/or progesterone. Other breast cancers are referred to as HER2-positive, which means that they overexpress the human epidermal growth factor receptor 2, a biologic pathway that is involved in replication and growth of a cell.. Breast cancers, on the other hand, that are not stimulated to grow from exposure to estrogen or progesterone and do not overexpress HER2 (HER2 negative) are called triple-negative breast cancers. Triple-negative breast cancers tend to be more aggressive than other ...
Objective: To analyze the implementation of a switching policy of adjuvant aromatase inhibitor (AI) therapy sequentially after tamoxifen in consecutively treated stage I (T1N0M0) hormone receptor (HR)-positive breast cancer (BC) patients. Methods: The records of 279 consecutive HR-positive BC patients diagnosed between 2002 and 2006 and followed at the Soroka Medical Center were reviewed. Results: Two-hundred-seventeen patients who initially received tamoxifen were suitable for switching and 28 received an AI as initial adjuvant treatment. The switch was accomplished in 82.5% of the 217 patients. Those who switched to an AI had a higher proportion of T1c stage than patients eligible who were not switched, but did not differ in age, histologic grade, or having received chemotherapy. Of the 179 patients who switched, 155 (86.6%) completed at least 4.5-5 years of adjuvant tamoxifen/AI therapy. Eighteen patients discontinued AI therapy prematurely because of toxicity. Conclusions: In this stage I BC ...
Trastuzumab has conferred significant clinical benefits in HER-2-positive breast carcinomas. HER-2 status is determined by immunohistochemistry (IHC) and/or fluorescence in situ hybridisation (FISH), but appropriate assessment of HER2 status remains subject to considerable debate. Data on the health economic impact of HER-2 test strategies are limited. A life-long Markov state transition model was used to assess costs and effectiveness of HER-2 assay strategies (based on IHC, FISH, both combined or FISH confirmation of IHC2+) for a hypothetical cohort of early breast cancer patients from the perspective of the Swiss health system. We compared clinically relevant strategies of predictive testing and subsequent trastuzumab treatment of HER-2-positive patients only. FISH testing was the most cost-effective strategy with an incremental cost-effectiveness ratio of ?12,245 per additional quality-adjusted life-year (QALY) gained, compared to no trastuzumab treatment. The next best strategy was parallel ...
The addition of the targeted therapy onartuzumab to Taxol® (paclitaxel) with or without Avastin® (bevacizumab) does not appear to help control disease or improve survival in patients with metastatic triple-negative breast cancer. These findings were published in the Annals of Oncology.. The majority of breast cancers are hormone receptor-positive, meaning that the cancer cells are stimulated to grow from exposure to the female hormones estrogen and/or progesterone. Other breast cancers are referred to as HER2-positive, which means that they overexpress the human epidermal growth factor receptor 2, a biologic pathway that is involved in replication and growth of a cell.. Breast cancers, on the other hand, that are not stimulated to grow from exposure to estrogen or progesterone and do not overexpress HER2 (HER2 negative) are called triple-negative breast cancers. Triple-negative breast cancers tend to be more aggressive than other breast cancers and have fewer treatment options because hormonal ...
The use of ultra-diluted natural products in the management of disease and treatment of cancer has generated a lot of interest and controversy. We conducted an in vitro study to determine if products prescribed by a clinic in India have any effect on breast cancer cell lines. We studied four ultra-diluted remedies (Carcinosin, Phytolacca, Conium and Thuja) against two human breast adenocarcinoma cell lines (MCF-7 and MDA-MB-231) and a cell line derived from immortalized normal human mammary epithelial cells (HMLE). The remedies exerted preferential cytotoxic effects against the two breast cancer cell lines, causing cell cycle delay/arrest and apoptosis. These effects were accompanied by altered expression of the cell cycle regulatory proteins, including downregulation of phosphorylated Rb and upregulation of the CDK inhibitor p27, which were likely responsible for the cell cycle delay/arrest as well as induction of the apoptotic cascade that manifested in the activation of caspase 7 and cleavage ...
Margolese RG, Fisher B, Hortobagyi GN, Bloomer WD (2000). "Neoplasms of the Breast". In Bast RC, Kufe DW, Pollock RE, et al. ( ... Mainly taken from risk factors for breast cancer, risk factors can be described in terms of, for example: Relative risk, such ... Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN (July 2004). "Breast carcinoma in men: a population-based study". ... of breast cancer cases are diagnosed in women." Increase in incidence in the exposed group, such as "each daily alcoholic ...
"Neoplasms of the Breast". {{cite journal}}: Cite journal requires ,journal= (help) Breast Cancer Collaborative Management. CRC ... He was a principal investigator and member of the Executive Committee of the National Surgical Adjuvant Breast Project, which, ... "Guideline 3: Mastectomy or lumpectomy? The choice of operation for clinical stages I and II breast cancer [Supplement, CMAJ - ... "Top Takeaways from ASCO: Breast Cancer". www.healio.com. Retrieved 2015-06-23. Margolese, Richard G.; Fisher, Bernard; ...
The World Health Organization (2019) classified papillary neoplasms (i.e. benign or cancerous tumors) of the breast into 5 ... Brogi E, Krystel-Whittemore M (January 2021). "Papillary neoplasms of the breast including upgrade rates and management of ... Tay TK, Tan PH (June 2021). "Papillary neoplasms of the breast-reviewing the spectrum". Modern Pathology. 34 (6): 1044-1061. ... Ross DS, D'Alfonso TM (March 2022). "Papillary Neoplasms of the Breast: Diagnostic Features and Molecular Insights". Surgical ...
Li F.P.; Fraumeni J.F. (October 1969). "Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?". Ann. ... Erratum for "Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms"". Science. 259 ( ... 1990). "Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms". Science. 250 (4985): ... except breast cancer if the proband has breast cancer) before age 56 years or with multiple tumors at any age Multiple tumors ( ...
They account for less than 1% of all breast neoplasms. This is predominantly a tumor of adult women, with very few examples ... Breast Cancer Study Group of the Institut Curie (2011). "Management of Phyllodes Breast Tumors". The Breast Journal. 17 (2): ... Tan PH, Thike AA, Tan WJ, Thu MM, Busmanis I, Li H, Chay WY, Tan MH (2012). "Predicting clinical behaviour of breast phyllodes ... Radiation treatment after breast-conserving surgery with negative margins may significantly reduce the local recurrence rate ...
Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 1969:71:747-752. Li FP, Fraumeni ... Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990:250: 1233-1238. ( ...
The incidence of mammary desmoid tumors is less than 0.2% of primary breast neoplasms. In Gardner's syndrome, the incidence ... The extra-abdominal form is rare and desmoids of the breast may arise in the mammary gland or may occur as an extension of a ... Rammohan A, Wood JJ (2012). "Desmoid tumour of the breast as a manifestation of Gardner's syndrome". Int J Surg Case Rep. 3 (5 ... Baranov E, Hornick JL (March 2020). "Soft Tissue Special Issue: Fibroblastic and Myofibroblastic Neoplasms of the Head and Neck ...
Fibromyoma of the breast is an extremely rare benign breast neoplasm. Most reports in literature mention a history of ... Mesenchymal neoplasms of the gallbladder are rare and in particular leiomyomas of the gallbladder have been rarely reported, ... ISBN 0-7216-2921-0. Radiologic Pathology Archives: Esophageal Neoplasms: Radiologic-Pathologic Correlation Rachel B. Lewis, ... Accessed 2017-07-08 Radiologic Pathology Archives: Esophageal Neoplasms: Radiologic-Pathologic Correlation Rachel B. Lewis, ...
The cancers included cancer of the brain, lung, bowel, breast, and bladder, and other neoplasms. It has been hypothesised[by ...
... breast carcinoma, and other neoplasms in young patients. Cancer developed in an autosomal dominant pattern in 151 blood ... "Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms". Science. 250 (4985): 1233-8. ... These neoplasms also accounted for 73% of the multiple primary cancers occurring in 15 family members. Six of these patients ... These young patients had a total of 50 bone and soft tissue sarcomas of diverse histological subtypes and 28 breast cancers. ...
"Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms". Science. 250 (4985): 1233-1238 ... Connective and soft tissue neoplasms, Small-blue-round-cell tumors, Sarcoma). ...
... neoplasm) in the fat-augmented breasts. Moreover, given the sensitive, biologic nature of breast tissue, periodic MRI and 3-D ... breast reduction, breast reconstruction, and liposuction of the breast. Nonetheless, detecting breast cancer is primary, and ... Therapy Breast augmentation via autologous fat grafts allows the oncological breast surgeon to consider conservative breast ... Post-cancer breast reconstruction After mastectomy, surgical breast reconstruction with autogenous skin flaps and with breast ...
It also confirms the genetic heterogeneity between the primary neoplasm of breast cancer patients and their respective ... 2003). Models of Breast Cancer: quo vadis, animal modeling? Breast Cancer Research 6(31), 31-38.doi: 10.1186/bcr723 Pulaski BA ... Fantozzi, A; Christofori, G (2006). "Mouse models of breast cancer metastasis". Breast Cancer Research. 8 (4): 212. doi:10.1186 ... Mice may not be an ideal model for breast cancer. This is mainly due to the lack of precision in many of the models. When ...
", "breast cancer" to "breast neoplasms". Where appropriate, these MeSH terms are automatically "expanded", that is, include ...
In 2009, an update including 5 more years (up to 1996) found an increase in "lymphatic and hematopoietic tissue neoplasms" and ... increased breast cancer. A 2008 study evaluated whether maternal exposure is associated with modified neonatal thyroid function ...
TTC39A has been tested for association to diseases like breast neoplasms and is expected to have molecular binding function and ... breast carcinoma, etc. There are five different transcript variants for the TTC39B gene. Isoform 1 is the longest transcript ...
... astrocytic neoplasms, phaeochromocytomas and breast cancer. No effective therapy NF1 yet exists. Instead, people with ... which develops myeloproliferative neoplasms similar to those found in NF1 juvenile myelomonocytic leukemia/JMML) were used to ... an oral selective MEK inhibitor used previously in several advanced adult neoplasms. The children enrolled in the study ...
Benign neoplasms, Breast neoplasia). ... The rate at which breast cancer (ductal carcinoma in situ or ... Atypical ductal hyperplasia (ADH) is the term used for a benign lesion of the breast that indicates an increased risk of breast ... Feb 1992). "A prospective study of benign breast disease and the risk of breast cancer". JAMA. 267 (7): 941-4. doi:10.1001/jama ... Ductal carcinoma in situ Breast cancer Collagenous spherulosis "Understanding Breast Changes - National Cancer Institute". ...
... skull base neoplasms MeSH C04.588.149.828 - spinal neoplasms MeSH C04.588.180.260 - breast neoplasms, male MeSH C04.588.180.390 ... bile duct neoplasms MeSH C04.588.274.120.250.250 - common bile duct neoplasms MeSH C04.588.274.120.401 - gallbladder neoplasms ... femoral neoplasms MeSH C04.588.149.721 - skull neoplasms MeSH C04.588.149.721.450 - jaw neoplasms MeSH C04.588.149.721.450.583 ... palatal neoplasms MeSH C04.588.149.721.600 - nose neoplasms MeSH C04.588.149.721.656 - orbital neoplasms MeSH C04.588.149.721. ...
... hCG was discovered to be expressed in certain kinds of malignant neoplasms, including breast cancer, adenocarcinoma of the ... Agnantis NJ, Patra F, Khaldi L, Filis S (1992). "Immunohistochemical expression of subunit beta HCG in breast cancer". Eur. J. ...
... benign and metastatic neoplasms (such as breast cancer, pancreatic cancer, and oral cancer), infectious conditions (such as HIV ... A 2000 study compared the salivary levels of a breast cancer marker (HER2/neu) in healthy women, women with benign breast ... compared saliva from breast cancer patients to that from healthy individuals and observed, notably, that breast cancer patients ... level of this marker was significantly higher in women with breast cancer than in healthy women and women with benign breast ...
... breast cyst MeSH C17.800.090.500 - breast neoplasms MeSH C17.800.090.500.260 - breast neoplasms, male MeSH C17.800.090.500.390 ... sebaceous gland neoplasms MeSH C17.800.882.743 - sweat gland neoplasms MeSH C17.800.893.592 - leg ulcer MeSH C17.800.893.592. ... carcinoma, ductal, breast MeSH C17.800.090.500.762 - phyllodes tumor MeSH C17.800.090.750 - fibrocystic breast disease MeSH ... sweat gland neoplasms The list continues at List of MeSH codes (C18). (Wikipedia articles in need of updating from February ...
Breast cancer, Epidermal nevi, neoplasms, and cysts). ... Breast changes. There may or may not be a lump in the breast, ... A breast-conserving surgery consists in the removal of the nipple, areola and the part of the breast that is affected by cancer ... Paget's disease of the breast is a type of cancer of the breast. Treatment usually involves a lumpectomy or mastectomy to ... Paget's disease of the breast can affect the nipple and areola. Symptoms typically only affect one breast. Symptoms may include ...
... for malignant neoplasm of breast and 2.2% for transport accident. The under 5 mortality rate was 8.3 per 1000 live birth in the ... and malignant neoplasm of trachea, bronchus & lung (2.2%). In 2016, the Ischemic heart disease was the principal cause of death ... malignant neoplasm of trachea, bronchus & lung. For women, the principal cause of death was pneumonia. Deaths due to pneumonia ...
B-cell neoplasm, breast carcinoma, Burkitt's lymphoma, colorectal adenocarcinoma, carcinoma, cutaneous T cell lymphoma, ...
A breast tumor is an abnormal mass of tissue in the breast as a result of neoplasia. A breast neoplasm may be benign, as in ... Signs of breast cancer may include a lump in the breast, a change in breast shape, dimpling of the skin, fluid coming from the ... Breast diseases make up a number of conditions. The most common symptoms are a breast mass, breast pain, and nipple discharge. ... Breast cancer is cancer of the breast tissues, most commonly arising from the milk ducts. Worldwide, breast cancer is the ...
"The 2016 revision of the World Health Organization classification of lymphoid neoplasms". Blood. 127 (20): 2375-2390. doi: ... Breast Breast augmentation (Augmentation mammoplasty) Breast enlargement supplements Breast reconstruction Breast reduction ... The breast implant has no clinical bearing upon lumpectomy breast-conservation surgery for women who developed breast cancer ... The breast cancer studies Cancer in the Augmented Breast: Diagnosis and Prognosis (1993) and Breast Cancer after Augmentation ...
"Overview of the 2022 WHO Classification of Thyroid Neoplasms". Endocrine Pathology. 33 (1): 27-63. doi:10.1007/s12022-022-09707 ... Invasive cribriform carcinoma of the breast (ICCB), also termed invasive cribriform carcinoma, is a rare type of breast cancer ... Erber R, Hartmann A (August 2020). "Histology of Luminal Breast Cancer". Breast Care (Basel, Switzerland). 15 (4): 327-336. doi ... and outcomes of special types in breast cancer in a single institution population". The Breast Journal. 26 (11): 2163-2169. doi ...
... liposuction mammoplasty also is contraindicated for any woman whose mammograms indicate the presence of unevaluated neoplasms; ... Medial Pedicle and Mastopexy Breast Reduction at eMedicine Breast Mastopexy at eMedicine Medial Pedicle and Mastopexy Breast ... from each breast, and the degree of breast ptosis present: Pseudoptosis (sagging of the inferior pole of the breast; the nipple ... when breast milk constitutes most of the breast volume. Surgically, the breast is an apocrine gland overlaying the chest - ...
Breast cysts (as occur commonly during pregnancy and at other times) are another example, as are other encapsulated glandular ... ICD-10 classifies neoplasms into four main groups: benign neoplasms, in situ neoplasms, malignant neoplasms, and neoplasms of ... The term neoplasm is a synonym of tumor. Neoplasia denotes the process of the formation of neoplasms/tumors, and the process is ... The process that occurs to form or produce a neoplasm is called neoplasia. The growth of a neoplasm is uncoordinated with that ...
Myung SK, Ju W, Kim SC, Kim H (October 2011). "Vitamin or antioxidant intake (or serum level) and risk of cervical neoplasm: a ... It is the second-most common cause of female-specific cancer after breast cancer, accounting for around 8% of both total cancer ...
Examples include: Brenner tumor of the ovary Fibroadenoma of the breast Phyllodes tumor of the breast Tavassoli, F.A., Devilee ... A fibroepithelial neoplasm (or tumor) is a biphasic tumor. They consist of epithelial tissue, and stromal or mesenchymal tissue ... World Health Organization Classification of Tumours: Pathology & Genetics: Tumours of the breast and female genital organs. ...
Breast cancer, colon cancer, and tumors of the female genital tract may metastasize to the appendix. Carcinoid tumors are the ... Mucinous cystadenoma is an obsolete term for appendiceal mucinous neoplasm. Small carcinoids (. ...
October 2012). "Comprehensive molecular portraits of human breast tumours". Nature. 490 (7418): 61-70. Bibcode:2012Natur.490... ... which is a myelodysplastic syndrome/myeloproliferative neoplasm). There is also an emerging body of evidence to suggest ... myelodysplastic syndromes and breast cancer. SF3B1 mutations are found in 60%-80% of patients with refractory anemia with ring ... "Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms". Blood ...
For example, neoplasms characterized by high-grade features, invasive glands and or signet ring cells, are termed ... breast, fallopian tubes, and the pancreas. This disease is often discovered during surgery for other conditions, e.g., hernia ... Young RH (May 2004). "Pseudomyxoma peritonei and selected other aspects of the spread of appendiceal neoplasms". Seminars in ... ISBN 978-0-323-35909-2. Sugarbaker PH (January 2006). "New standard of care for appendiceal epithelial neoplasms and ...
It induced regression in 20% of women with advanced breast cancer at a dosage of 300 mg/day orally. Flugestone Fluorometholone ... "Pharmacology and Clinical Utility of Hormones in Hormone Related Neoplasms". In Alan C. Sartorelli; David G. Johns (eds.). ... Similarly to various other progestogens, BKP has been studied in the treatment of breast cancer in women.: 185 Evaluated in ... 9α-Bromo-11-oxoprogesterone (bromoketoprogesterone) given in a dose of 300 mg orally daily in patients with advanced breast ...
Along with neoplasms of the sebaceous gland, this patient developed cerebral neoplasms, characteristic of Turcot syndrome. ... and Breast (4%). A variety of other internal malignancies have been reported. A couple studies have been conducted on patients ... Colorectal cancer is the most common visceral neoplasm in Muir-Torre syndrome patients. It is named for EG Muir and Douglas ... Age of onset of first sebaceous neoplasm: 2 = 2 points. Personal history of Lynch related cancers: No = 0 points, Yes = 1 point ...
However, p16 can be expressed in other neoplasms and in several normal human tissues. More than a third of urinary bladder SCCs ... CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients". Life Sciences. 80 (20): 1873-81. doi:10.1016/j.lfs. ... infection and neoplasms of cervical origin. The majority of SCCs of uterine cervix express p16. ...
Myxomas may also occur outside the heart, usually in the skin and breast. Endocrine tumors may manifest as disorders such as ... Melanocytic nevi and neoplasms, Syndromes affecting the skin, Syndromes affecting the heart, Syndromes with tumors). ... "Pancreatic ductal and acinar cell neoplasms in Carney complex: a possible new association". J Clin Endocrinol Metab. 96 (11): ... Epithelioid blue nevus List of cutaneous neoplasms associated with systemic syndromes Carney Syndrome at eMedicine Carney, J.; ...
"Hormone Therapy for Breast Cancer , Breast Cancer Treatment". www.cancer.org. Retrieved 2022-04-28. Hammerstrom AE, Cauley DH, ... "Male Genitals - Prostate Neoplasms". Pathology study images. University of Virginia School of Medicine. Archived from the ... In Europe in 2012, it was the third-most diagnosed cancer after breast and colorectal cancers at 417,000 cases. In the United ... Mutations in BRCA1 and BRCA2 (important risk factors for ovarian cancer and breast cancer in women) have also been implicated. ...
In premenopausal women, elevated prolactin can lead to reduction or loss of menstrual periods and/or breast milk production ( ... usually suprasellar neoplasm, which may be cystic, that develops from nests of epithelium derived from Rathke's pouch. Rathke's ...
... or breast implants (e.g. breast swelling/pain/malformation). While most cases of classical PEL involve one cavitary site, some ... This lymphoma also belongs to a group of lymphoid neoplasms with plasmablastic differentiation that involve malignant ... List of hematologic conditions Chen BJ, Chuang SS (March 2020). "Lymphoid Neoplasms With Plasmablastic Differentiation: A ... which forms around breast implants. Less frequently, individuals present with extracavitary primary effusion lymphomas, i.e., ...
"Breast feeding reduces risk of breast cancer, says study," British Medical Journal, v.); Jul 27, 2002 Shaw, Palma; Duncan, ... Several severe adverse health effects, such as an increased incidence of cancers, thyroid diseases, CNS neoplasms, and possibly ... A related concern is that radionuclides that may be passed through the breast milk, causing some women who are downwinders to ... The increased radiosensitivity of certain organs in women, such as the breast, ovaries, and thyroid is likely the cause of this ...
Blastic plasmacytoid dendritic cell neoplasm is a rare type of myeloid cancer in which malignant pDCs infiltrate the skin, bone ... and similar abnormalities in breasts, eyes, kidneys, lungs, gastrointestinal tract, bone, sinuses, ears, and/or testes. The ... Wang S, Wang X, Liu M, Bai O (April 2018). "Blastic plasmacytoid dendritic cell neoplasm: update on therapy especially novel ... Blastic plasmacytoid dendritic cell neoplasm has a high rate of recurrence following initial treatments with various ...
Renal epithelial neoplasms have characteristic cytogenetic aberrations that can aid in classification. See also Atlas of ... and sequence alterations in breast and colorectal cancers". Proc Natl Acad Sci U S A. 105 (42): 16224-9. Bibcode:2008PNAS.. ... "Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms." Nature 13 Aug 2009; 460, 904-909. Gondek LP, Tiu R, ... Malignant rhabdoid tumors are rare, highly aggressive neoplasms found most commonly in infants and young children. Due to their ...
Baranov E, Hornick JL (March 2020). "Soft Tissue Special Issue: Fibroblastic and Myofibroblastic Neoplasms of the Head and Neck ... and chest wall/breast. While typically presenting as slow growing, painless masses, some individuals have presented with ... "Practical approach to diagnosis of bland-looking spindle cell lesions of the breast". Pathologica. 111 (4): 344-360. doi: ...
Radiation to the breast reduces the ability of that breast to produce milk and increases the risk of mastitis. Also, when ... They form a subset of neoplasms. A neoplasm or tumor is a group of cells that have undergone unregulated growth and will often ... for breast cancer, see Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, et al. (February 2009). "Breast ... Recommends mammography for breast cancer screening every two years from ages 50-74, but does not recommend either breast self- ...
Kales SC, Ryan PE, Nau MM, Lipkowitz S (June 2010). "Cbl and human myeloid neoplasms: the Cbl oncogene comes of age". Cancer ... is an E3 ubiquitin ligase that overexpression has been shown to be the major cause of estrogen-independent breast cancer. Efp's ... "The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation". The Journal of ... "DNA copy number losses in human neoplasms". The American Journal of Pathology. 155 (3): 683-94. doi:10.1016/S0002-9440(10)65166 ...
... is a high-risk premalignant lesion of the breast. It is believed that atypical ductal hyperplasia (ADH) is ... Benign neoplasms). ...
Normal breast tissue does not express H19 RNA, except during puberty and pregnancy in the mammary glands. However, in breast ... In contrast to most other cancers, adrenocortical neoplasms appear to have decreased expression of H19. To determine a possible ... "Breast Cell Line MCF-7". Cancer Biology - Breast Cancer Cell Line Database. University of Texas M. D. Anderson Cancer Center. ... In experiments conducted by Doyle et al., it was found that MCF-7, a breast adenomacarcinoma cell line, did not express the H19 ...
FEN1 is upregulated in the majority of cancers of the breast, prostate, stomach, neuroblastomas, pancreas, and lung.[citation ... Such mutations and epigenetic alterations can give rise to cancer (see malignant neoplasms).[verification needed] Investigation ...
2nd Neoplasms (accounting for 172.8 deaths per 100,000 population) and 3rd Chronic Respiratory Disease (59.25 deaths per ... a higher incidence than conditions such as breast cancer, prostate cancer, diabetes and AIDS combined within that age range. ... 2nd Neoplasms (accounting for 201.65 deaths per 100,000 population), 3rd Neurological Disorders (accounting for 76.18 deaths ... neoplasms - 3,751 DALYs per 100,000 population mental disorders - 3,216 DALYs per 100,000 musculoskeletal disorders - 2,956 ...
For example, for breast cancer after breast-conserving surgery, radiotherapy has been found to halve the rate at which the ... Hypopituitarism commonly develops after radiation therapy for sellar and parasellar neoplasms, extrasellar brain tumours, head ... "Intraoperative radiation therapy for breast cancer patients: current perspectives". Breast Cancer: Targets and Therapy. 9: 257- ... 2005). "Breast cancer". In Gerbaulet A, Pötter R, Mazeron J, Limbergen EV (eds.). The GEC ESTRO handbook of brachytherapy. ...
Autoimmune estrogen dermatitis Autoimmune progesterone dermatitis Autosensitization dermatitis Breast eczema (nipple eczema) ... neoplasms, and cysts are skin lesions that develop from the epidermal layer of the skin. Aberrant basal cell carcinoma ... an overview with emphasis on the myeloid neoplasms". Chem. Biol. Interact. 184 (1-2): 16-20. doi:10.1016/j.cbi.2009.10.009. ... neoplasms invading or aberrantly present in the dermis. Acquired progressive lymphangioma (benign lymphangioendothelioma) Acral ...
Gibbon-ape leukemia virus (GaLV) is an oncogenic, type C retrovirus that has been isolated from primate neoplasms, including ... FeLV is horizontally and vertically transmitted through biomaterials; saliva, blood, breast milk, urine and feces. Furthermore ... The virus was identified as the etiological agent of hematopoietic neoplasms, leukemias, and immune deficiencies within gibbons ...
Wang S, Wang X, Liu M, Bai O (April 2018). "Blastic plasmacytoid dendritic cell neoplasm: update on therapy especially novel ... and similar abnormalities in breasts, eyes, kidneys, lungs, gastrointestinal tract, bone, sinuses, ears, and/or testes. The ... Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare type of myeloid cancer in which malignant pDCs infiltrate the ... pDCs that undergo malignant transformation cause a rare hematologic disorder, blastic plasmacytoid dendritic cell neoplasm. In ...
... 0-9. A. B. C. D. E. F. G. H. I. J. K. L. M. N. O. P. Q. R. S. T. U. V ... Policy statement and recommended actions for early detection of breast cancer in the Eastern Mediterranean Region  ... Policy statement and recommended actions for early detection of breast, cervical, colorectal, oral and prostate cancers in the ...
Breast cancer is the most common malignant neoplasm affecting women in Bahrain. We studied the demographic characteristics and ... Breast self-examination practice and its impact on breast cancer diagnosis in Alexandria, Egypt  ... Breast cancer prognosis in Salah Azaiez Institute of Cancer, Tunis]‎  Ben Gobrane, H.; Fakhfakh, R.; Rahal, K.; Ben Ayed, F.; ... Breast cancer is the commonest type of malignancy in Iraq. The study was carried out on 721 out of a total of 5044 patients [‎ ...
breast benign neoplasm (DOID:0060082) Alliance: disease page Definition: A thoracic benign neoplasm that is characterized by ...
Digitally Distributed Yoga for Women Treated for Breast Cancer ... Yes for Clinical diagnosed with breast cancer Adult women Must ... Not sure for Clinical diagnosed with breast cancer Adult women Must have undergone breast cancer surgery inclusion criteria 1 ... No for Clinical diagnosed with breast cancer Adult women Must have undergone breast cancer surgery inclusion criteria 1 ... Clinical diagnosed with breast cancer Adult women Must have undergone breast cancer surgery. ...
ICD 10 code for Neoplasm of uncertain behavior of breast. Get free rules, notes, crosswalks, synonyms, history for ICD-10 code ... neoplasm of uncertain behavior of cartilage of nose (D38.5). *neoplasm of uncertain behavior of connective tissue of breast ( ... Neoplasm of uncertain behavior of breast. 2016 2017 2018 2019 2020 2021 2022 2023 Non-Billable/Non-Specific Code *D48.6 should ... For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, ...
FERREIRA, Naidhia Alves Soares et al. Inflammatory breast neoplasms: a systematic review. Rev. bras. crescimento desenvolv. hum ... "Inflammatory Breast Neoplasms" (MeSH Terms), filtered by Languages (English OR Portuguese OR Spanish). FINDINGS: Of the ... OVERVIEW: Inflammatory Breast Cancer (IBC) is a rare and very aggressive type of cancer that tends to develop at a younger age ... compared with other subtypes of breast cancer. Because a distinct lump may not be noticeable, correct diagnosis takes longer ...
Benign and malignant breast neoplasms. Primary tabs. *Innovative solutions (5)(active tab) ... You are looking for all the solutions related to Benign and malignant breast neoplasms ...
Oral contraceptives & breast cancer / Committee on the Relationship between Oral Contraceptives and Breast Cancer, Institute of ... Smoking and breast cancer / Jonas Manjer. by Manjer, Jonas.. Material type: Text; Format: print Publication details: Malmö : ... Breast cancer screening / [editor] Ismail Jatoi. by Jatoi, Ismail.. Material type: Text; Format: print Publication details: ... Prevention of breast cancer / Ian S. Fentiman. by Fentiman, Ian S.. Series: Medical intelligence unitMaterial type: Text; ...
View information on a Breast Neoplasms clinical trial: Pfizer study NCT05478590. See if you may be eligible. ... Breast Neoplasms. Who may participate. Each clinical study has its own guidelines for who may participate, called eligibility ... Breast Neoplasms. The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions ... A Study to Describe Treatment Patterns of Advanced Breast Cancer in Poland in the Real-world Data Setting. NCT# stands for ...
... Disease. Medical Tests (20). Access to Malignant neoplasm, male breast is restricted. Sign up ...
Our results suggest that the functional IGFBP3 A-202C polymorphism may influence the susceptibility and progression of breast ... Breast Neoplasms / genetics* * Breast Neoplasms / pathology* * Case-Control Studies * Female * Gene Frequency / genetics ... Impact of the IGFBP3 A-202C polymorphism on susceptibility and clinicopathologic features of breast cancer Biomed Pharmacother ... Methods: We genotyped the IGFBP3 A-202C polymorphism in a case-control study involving 465 breast cancer patients and 799 age- ...
Although breast cancer is much more common in women, men can get it too. Learn more. ... Did you know that men can get breast cancer? ... ClinicalTrials.gov: Breast Neoplasms, Male (National Institutes ... Breast lumps usually arent cancer. However, most men with breast cancer have lumps. Other breast symptoms can include:. * ... Breast Biopsy (National Library of Medicine) Also in Spanish * Can Breast Cancer in Men Be Found Early? (American Cancer ...
Hoda The preoperative clinical workup of an apparently healthy patient with a breast mass can be cursory and is unlikely to ... Metastases in the Breast from Nonmammary Malignant Neoplasms Syed A. ... Hematopoietic and lymphoid neoplasms involving the breast are sometimes listed under the rubric of breast "metastases," but ... If hematopoietic and lymphoid neoplasms are excluded, the most common NMMNs that secondarily involve the breast include ...
Breast Neoplasms. Atwell LL, Zhang Z, Mori M, Farris P, Vetto JT, Naik AM, Oh KY, Thuillier P, Ho E, Shannon J. 2015. ... Prostatic Neoplasms. Preble I, Zhang Z, Kopp R, Garzotto M, Bobe G, Shannon J, Takata Y. 2019. Dairy Product Consumption and ... Sulforaphane Bioavailability and Chemopreventive Activity in Women Scheduled for Breast Biopsy.. Cancer Prev Res (Phila). 8(12 ... Sulforaphane Bioavailability and Chemopreventive Activity in Women Scheduled for Breast Biopsy.. Cancer Prev Res (Phila). 8(12 ...
Breast Neoplasms, Male (7). Carcinoma, Ductal, Breast (2). Hereditary Breast and Ovarian Cancer Syndrome (1) ... Breast Neoplasms. Guidelines by Topic. Disease/Condition , Diseases (2488) , Neoplasms (653) , Neoplasms by Site (502) , ... Familial breast cancer: classification and care of people at risk of familial breast cancer and management of breast cancer and ... consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast ...
Malignant neoplasm of breast. C50.P. prevent breast cancer. C61. Malignant neoplasm of prostate. ...
... health guidelines resulted in reduced adiposity levels in previously sedentary postmenopausal women at higher risk of breast ... exercise intervention on adiposity outcomes that may be involved in the association between physical activity and breast cancer ... Table 1 Characteristics of participants at baseline in the Alberta Physical Activity and Breast Cancer Prevention Trial, n=320 ... Ballard-Barbash R, Swanson CA . Body weight: estimation of risk for breast and endometrial cancers. Am J Clin Nutr 1996; 63: ...
SUDAN predictors of breast cancer were: age, menarche, family history, vegetables and fruits weekly servings, and type of ... we therefore aimed to develop and validate a tool for breast cancer risk assessment among Sudanese women. Using cross-sectional ... efficient and well-calibrated tool to predict and classify womens lifetime risks of developing breast cancer. Input from our ... Breast cancer risk prediction models are widely used in clinical settings. Although most of the well-known models were designed ...
Breast Neoplasms * Colorectal Neoplasms * Dose Fractionation, Radiation * Female * Head and Neck Neoplasms ... The primary involved organs were the lung (n = 15), colorectum (n = 9), head and neck (n = 5), kidney (n = 3), breast (n = 1), ...
The Australian Breast Cancer Family Study (ABCFS), the British Breast Cancer Study (BBCS), the Breast and Prostate Cancer ... Primary Phenotype: Breast Neoplasms Links to Related Resources * BioProject * PubMed * MeSH * PMC ... the Singapore and Sweden Breast Cancer Study (SASBAC), the Triple Negative Breast Cancer Study (TNBC), and the UK2 GWAS. These ... German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC), the Helsinki breast cancer family Study (HEBCS), the ...
Synonyms: malignant neoplasm of overlapping sites of breast, malign ... Billable ICD-10 code to specify malignant neoplasm of overlapping sites of unsp male breast. ... Malignant neoplasm of central portion of breast. NON-BILLABLE CODE. C50.11. Malignant neoplasm of central portion of breast, ... Malignant neoplasm of overlapping sites of breast. *Neoplasm of breast primary tumor staging category T4: Direct extension to ...
ICD-10 code C50.421 for Malignant neoplasm of upper-outer quadrant of right male breast online definition ... ICD-10 code C50.421 for Malignant neoplasm of upper-outer quadrant of right male breast ... Malignant neoplasms, stated or presumed to be primary (of specified sites), and certain specified histologies, except ...
Breast Feeding [‎12]‎. Breast Neoplasms [‎1]‎. Budgets [‎763]‎. Burkina Faso [‎178]‎. Burundi [‎28]‎. ...
Breast Neoplasms. Neoplasms by Site. Neoplasms. Breast Diseases. Skin Diseases. Fulvestrant. Antineoplastic Agents, Hormonal. ... advanced breast cancer. alpelisib. fulvestrant. PI3K. Phase III. ER+. PgR+. men. postmenopausal. aromatase inhibitor. neoplasms ... newly diagnosed advanced breast cancer, then relapsed with documented evidence of progression while on or after only one line ... Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast ...
Breast Neoplasms. Neoplasms by Site. Neoplasms. Breast Diseases. Skin Diseases. Talazoparib. Poly(ADP-ribose) Polymerase ... Metastatic breast cancer with deleterious somatic BRCA 1 or 2 mutations detectable by cell-free circulating tumor DNA, by CLIA ... Triple negative breast cancer (defined as ER , 1%, PR , 1%, HER2 negative, as per ASCO CAP guidelines), with disease ... At least two weeks from last systemic therapy for breast cancer, with recovery of all treatment related toxicity to grade 1 or ...
N0 breast cancer were treated with breast-conserving surgery and breast irradiation, between January 1, 1985, and December 31, ... For patients with positive resection margins, the time intervals from breast surgery to breast irradiation used for analysis ... Patients with positive resection margins have higher local recurrence rates that become apparent when breast irradiation is ... The aim of this study was to determine the effect of timing of radiotherapy after conservative breast surgery on local ...
The main aim of this study is to find out the various histopathological patterns and distribution of neoplastic breast lesions ... Histopathological patterns of breast neoplasms: A study in tertiary care hospital. Int J Clin Diagn Pathol 2020;3(2):24-29. DOI ... Histopathological patterns of breast neoplasms: A study in tertiary care hospital. Dr. Hima Bindu Gurram, Dr. Yarlagadda ... The main aim of this study is to find out the various histopathological patterns and distribution of neoplastic breast lesions ...
Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?. Ann Intern Med. 1969 Oct. 71(4):747-52. [QxMD ... Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990 Nov 30. 250(4985 ... Breast self-examination training and regular monthly breast self-examination, starting at age 18 years. [31] ... Excess risk of breast cancer in the mothers of children with soft tissue sarcomas. Br J Cancer. 1984 Mar. 49(3):325-31. [QxMD ...
  • Carcinoma of the breast is the most prevalent cancer among Egyptian women and constitutes 29% of National Cancer Institute cases. (who.int)
  • Breast carcinoma : risk and detection / Cushman D. Haagensen, Carol Bodian, Darrow E. Haagensen. (who.int)
  • Metastasis from the contralateral breast is a diagnostic consideration when there is bilateral involvement (or history thereof), the histologic appearances of the tumors in the breasts are similar, and there is no evidence of in situ carcinoma in the contralateral breast. (basicmedicalkey.com)
  • Radiologic techniques such as MRI (magnetic resonance imaging) and FDG-PET/CT (fluorodeoxyglucose-positron emission tomography-computed tomography) have also detected metastases in the breast from carcinoma of the thyroid ( 7 ), ovary ( 8 ), and soft tissue liposarcoma ( 9 ). (basicmedicalkey.com)
  • Melanoma arising in the breast is usually a form of metaplastic carcinoma, and it may therefore express cytokeratin. (basicmedicalkey.com)
  • The protocol includes frequent laboratory and radiographic screening for adrenocortical carcinoma, brain tumors, soft-tissue and bone sarcoma, leukemia/lymphoma, breast cancer, and colon cancer. (medscape.com)
  • Els H, Breast carcinoma. (radiopaedia.org)
  • Positive family history of breast carcinoma. (radiopaedia.org)
  • 516 biopsy confirmed, newly diagnosed patients with primary carcinoma of the breast constituted the cases, while the controls were 516 women matched for age (+ 5 years to that of the case) without breast cancer living in close vicinity. (who.int)
  • In breast invasive carcinoma (BRCA) and liver hepatocellular carcinoma (LIHC), high YIF1B expression correlated with a poor disease-free interval (DFI), indicating a role in malignancy progression. (silverchair.com)
  • A type of tumor found in breast or prostate tissue. (icd10data.com)
  • Breast cancer is a disease in which certain cells in the breast become abnormal and multiply uncontrollably to form a tumor. (icdlist.com)
  • In this research study, the investigators are examining how effective talazoparib is in patients with metastatic breast cancer with a BRCA mutation in their tumor. (clinicaltrials.gov)
  • At that time, a needle biopsy of the breast tumor or a sentinel (underarm) lymph node biopsy will also be performed. (knowcancer.com)
  • The aims of the project are 1) to identify and understand novel mechanisms regulating breast cancer cell death and 2) to identify molecular patterns of importance for the tumor biology and disease outcome. (lu.se)
  • Patients with advanced, histologically confirmed pancreatic, breast, non-small-cell lung cancer (NSCLC), gastric, esophageal, head and neck, or ovarian tumors that recurred after or has been refractory to prior therapy (fresh tumor biopsy or an archived sample testing for Nectin-4 expression). (bcan.org)
  • The prognostic significance of tumor-infiltrating lymphocytes (TILs) has been determined in breast cancers. (e-crt.org)
  • High expression of MxA in tumor cells was associated with high levels of TILs in HER2-positive breast cancers. (e-crt.org)
  • The purpose of this study is to determine if a combination of two drugs ipatasertib and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulating tumor DNA in the blood. (survivornet.com)
  • Definitive breast surgery must have been performed and includes lumpectomy or mastectomy with pathologically clear margins (i.e. no ink on tumor). (survivornet.com)
  • The example below shows malignant neoplasm of breast detailed with laterality and specific anatomy. (who.int)
  • In both women and men, the most common form of breast cancer begins in cells lining the milk ducts (ductal cancer). (icdlist.com)
  • The preoperative clinical workup of an apparently healthy patient with a breast mass can be cursory and is unlikely to exclude a metastasis from a clinically inapparent (that is, "occult") nonmammary malignant neoplasm (NMMN). (basicmedicalkey.com)
  • Thus, when faced with a mammary neoplasm that has unusual clinical, radiologic, or histologic features, it is important to consider metastasis in the differential diagnosis. (basicmedicalkey.com)
  • In approximately one-third of the cases, the metastasis in the breast is the first presentation of the NMMN. (basicmedicalkey.com)
  • Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial. (cam.ac.uk)
  • 2015. Inflammatory Biomarkers, Comorbidity, and Neurocognition in Women With Newly Diagnosed Breast Cancer. . (ucla.edu)
  • ACR Appropriateness Criteria® stage I breast cancer: initial workup and surveillance for local recurrence and distant metastases in asymptomatic women. (blogspot.com)
  • Purpose: The aim of this study was to determine the effect of timing of radiotherapy after conservative breast surgery on local recurrence in women with positive resection margins and young age, treated without systemic therapy. (bepress.com)
  • Patients with positive resection margins have higher local recurrence rates that become apparent when breast irradiation is delayed. (bepress.com)
  • Although most women with luminal breast cancer do well on endocrine therapy alone, some will develop fatal recurrence thereby necessitating the need to prospectively determine those for whom additional cytotoxic therapy will be beneficial. (elsevier.com)
  • Despite methodological differences, findings evidence that although IBC presents particular features (lower survival rate and worse prognostics than most types of breast cancer), very few studies examine its epidemiology and specific risk factors in depth and use any other therapeutic approaches than those commonly used for other breast cancer subtypes. (bvsalud.org)
  • Breast cancer : epidemiology, endocrinology, biochemistry and pathobiology / Helmuth Vorherr. (who.int)
  • Breast and gynecologic cancer epidemiology / authors, Jennifer L. Kelsey, Nancy G. Hildreth. (who.int)
  • DE SILVA, AASO, Some aspects in the epidemiology of breast cancer in women Sri Lanka, Post Graduate Institute of Medicine, Colombo PGIM , 1992: p. (who.int)
  • If hematopoietic and lymphoid neoplasms are excluded, the most common NMMNs that secondarily involve the breast include carcinomas of the lung, ovary, stomach, kidney, and cutaneous melanoma. (basicmedicalkey.com)
  • Among the metastatic carcinomas in the breast that are most likely to be mistaken for a breast primary are those arising in the lung, ovary, mullerian system, and bowel. (basicmedicalkey.com)
  • The primary involved organs were the lung (n = 15), colorectum (n = 9), head and neck (n = 5), kidney (n = 3), breast (n = 1), and bone (n = 1). (nih.gov)
  • Risk factors associated with the leading causes of cancer death include tobacco use (lung, colorectal, stomach, and liver cancer), overweight/obesity and physical inactivity (breast and colorectal cancer), and infection (liver, stomach, and cervical cancer). (nih.gov)
  • Patients with breast cancer, colorectal cancer, or lung cancer were recruited to complete the EQ-5D-3L and EQ-5D-5L questionnaires. (bsl.nl)
  • A total of 1802 cancer patients (breast cancer: 601, colorectal cancer: 601, lung cancer: 600) were included, with the mean age of 55.6 years. (bsl.nl)
  • With these static MLC fields creating the intensity modulation, the dose uniformity to the breast can be significantly improved and the hot region in lung reduced. (iaea.org)
  • A thoracic benign neoplasm that is characterized by lack of malignancy. (jax.org)
  • Categories D37 - D44 , and D48 classify by site neoplasms of uncertain behavior, i.e., histologic confirmation whether the neoplasm is malignant or benign cannot be made. (icd10data.com)
  • A benign, borderline, or malignant fibroepithelial neoplasm arising from the breast and rarely the prostate gland. (icd10data.com)
  • Most breast masses in adolescents are benign and self-limited. (pediatriconcall.com)
  • K) Women who had a positive history of benign breast disease were at an increased risk of breast cancer relative to women who did not have such a history. (who.int)
  • The Effect of Timing of Radiotherapy after Breast-conserving Surgery in Patients with Positive or Close Resection Margins, Young Age, and Node-negative Disease, with Long Term Follow-up" International Journal of Radiation Oncology, Biology, Physics Vol. 66 Iss. (bepress.com)
  • The stratified randomization will be according to surgery, Breast-Conserving Surgery (BCS) versus mastectomy (ME), chemotherapy versus no chemotherapy. (centerwatch.com)
  • Primary management of breast cancer : alternatives to mastectomy / edited by Jeffrey S. Tobias and Michael J. Peckham. (who.int)
  • Treatment for male breast cancer is usually a mastectomy, which is surgery to remove the breast. (icdlist.com)
  • After completing 4 cycles (12 weeks) of capecitabine, patients will then undergo surgery to remove any remaining breast cancer (lumpectomy or mastectomy). (knowcancer.com)
  • It is essential to have a deep knowledge in pediatric breast pathology to provide the most adequate treatment to each patient. (pediatriconcall.com)
  • Hematopoietic and lymphoid neoplasms involving the breast are sometimes listed under the rubric of breast "metastases," but they are best regarded as either primary breast neoplasms or as a manifestation of a systemic condition, depending upon the extent of organ involvement. (basicmedicalkey.com)
  • Reproductive factors and risk of cancers of the breast and genital organs : a prospective study of Norwegian women / by Gunnar Kvale. (who.int)
  • PURPOSE: Common resistance mechanisms to endocrine therapy (ET) in estrogen receptor (ER)-positive metastatic breast cancers include, among others, ER loss and acquired activating mutations in the ligand-binding domain of the ER gene (ESR1LBDm). (cam.ac.uk)
  • We utilize public data as and molecular data generated within the SCANB project, a continuous collection of consecutive material of breast cancers operated in Southern Sweden. (lu.se)
  • Skin cancer, male genital system cancers, and in situ neoplasms (e.g., skin and breast) are the most common WTC-related certified cancer conditions. (cdc.gov)
  • Today, we recognize that ER-positive breast cancers and ER-negative breast cancers constitute different diseases [1]. (2medicalcare.com)
  • Here,we evaluated TILs and MxA expression in human epidermal growth factor receptor 2 (HER2)-positive breast cancers. (e-crt.org)
  • High levels of TILs were also associated with improved disease-free survival, particularly in HR-/HER2+ breast cancers. (e-crt.org)
  • The prognostic significance of TILs has been determined in breast cancers, particularly human epidermal growth factor receptor 2 (HER2)-positive breast cancers and triple-negative breast cancers [ 1 ]. (e-crt.org)
  • Based on this background, a group of investigators around the world convened to discuss the parameters and methodological issues associated with evaluating TILs in breast cancers [ 4 ] and released recommendations for their evaluation. (e-crt.org)
  • The U.S. Food and Drug Administration (FDA) has not approved atezolizumab (Tecentriq) for residual triple negative breast cancer but it has been approved for advanced triple negative breast cancer and other cancers. (survivornet.com)
  • Determine all-cause mortality compared to the general male population and analyze survival/mortality compared with Danish female breast cancer patients (FBCP) in the same period. (aau.dk)
  • which was evidenced in a national survey, Breast cancer is one of the most which analyzed the growth of the mortality incidents in the world and the most frequent rate from the disease in Brazil, in which an among women. (bvsalud.org)
  • It varies widely between individuals, is a heritable trait and is associated with risks for obesity, type 2 diabetes, cardiovascular disease, breast cancer and all-cause mortality. (unc.edu)
  • 3.0 × 10(-3) were selected for replication using pooled case-control data from 11 studies of the Breast Cancer Association Consortium, including 7689 cases (676 lobular) and 9266 controls. (qub.ac.uk)
  • Risk factors for male breast cancer include exposure to radiation, a family history of breast cancer, and having high estrogen levels, which can happen with diseases like cirrhosis or Klinefelter syndrome. (icdlist.com)
  • For instance, a population-based nested case-control study involving breast cancer survivors showed that obesity, alcohol intake and smoking increased the risk of a second breast cancer appreciably. (cmaj.ca)
  • 2015. Depression and vasomotor symptoms in young breast cancer survivors: the mediating role of sleep disturbance. . (ucla.edu)
  • 2015. Mindfulness meditation for younger breast cancer survivors: a randomized controlled trial. . (ucla.edu)
  • 2015. Motivations associated with physical activity in young breast cancer survivors. . (ucla.edu)
  • 2015. Psychological Adjustment in Breast Cancer Survivors. . (ucla.edu)
  • 2014. Childhood adversity and inflammation in breast cancer survivors. . (ucla.edu)
  • 2014. Low heart rate variability and cancer-related fatigue in breast cancer survivors. . (ucla.edu)
  • 2014. Tai chi, cellular inflammation, and transcriptome dynamics in breast cancer survivors with insomnia: a randomized controlled trial. . (ucla.edu)
  • 2014. Yoga reduces inflammatory signaling in fatigued breast cancer survivors: a randomized controlled trial. . (ucla.edu)
  • For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned. (icd10data.com)
  • As a result, metastatic tumors cannot be distinguished radiologically from circumscribed primary breast carcinomas, particularly those of the papillary, medullary, or mucinous types. (basicmedicalkey.com)
  • Some types of breast tumors such as small cell, adenoid cystic, and mucoepidermoid carcinomas can occur in other organs, and appropriate clinical workup is prudent in these cases. (basicmedicalkey.com)
  • Guerreiro F P, Martins M, Rasteiro D, Pires P R, Ladeira C. Tumors of the Adolescent Breast - Regarding a Clinical Case. (pediatriconcall.com)
  • Tumors or cancer of the human BREAST . (bvsalud.org)
  • Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified ( C25.9 ). (icd10data.com)
  • Clinical Trial for Breast Neoplasms. (pfizerclinicaltrials.com)
  • The main goals are to assess the current treatment patterns of hormone receptor-positive (HR+) Human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer and their changes in clinical practice and relate them to patients' demographics, disease characteristics, type of other therapies used in patients as well as disease progression and visceral crisis occurrence. (pfizerclinicaltrials.com)
  • A physical exam, including a clinical breast exam (CBE). (medlineplus.gov)
  • Metastases from NMMN are rare and account for less than 1% of all mammary malignant neoplasms in clinical series, and up to 5% of autopsies of patients who die as a result of NMMN ( 1 ). (basicmedicalkey.com)
  • Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. (blogspot.com)
  • Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. (blogspot.com)
  • Evidence-based clinical practice guideline: breast reconstruction with expanders and implants. (blogspot.com)
  • Breast cancer risk prediction models are widely used in clinical settings. (biomedcentral.com)
  • Clinical evaluation can be particularly challenging due to normal breast tissue development and natural changes. (pediatriconcall.com)
  • See CLINICAL STUDIES and WARNINGS, Cardiovascular Disorders and Malignant Neoplasms, Breast Cancer. (nih.gov)
  • These findings enhance the value of the IHC4-score as an adjunct to clinical prognostication tools for aiding chemotherapy decision-making in luminal breast cancer patients, irrespective of subtype. (elsevier.com)
  • Anatomopathological evaluation of the surgical specimens of mammoplasties may be important for the detection of breast tissue changes without previous clinical manifestations, but in our series there were no cases of malignancies, and this conduct should be discussed. (rbcp.org.br)
  • The M group shows the worst outcomes and the IM genetic analysis of breast cancer is not easily available in clinical group shows the best outcomes [8]. (2medicalcare.com)
  • as a treatment for B-cell neoplasms have shown some promising results in clinical trials, their clinical use is limited, partially due to the risk of cytokine-release syndrome (CRS) occurring in response to the treatment. (ajmc.com)
  • It has been applied to the clinical service by utilizing DHPLC for the genetic diagnosis of BRCA1 and BRCA2 of breast cancer patients in the department of Genetic Medicine of our hospital. (knowcancer.com)
  • Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. (blogspot.com)
  • The Women's Health Initiative (WHI) estrogen plus progestin substudy reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone acetate (MPA 2.5 mg) relative to placebo. (nih.gov)
  • Pathologically confirmed residual invasive breast cancer, in the breast and/or lymph node(s), following neoadjuvant chemotherapy. (survivornet.com)
  • Breast cancer happens when there are changes in the genetic material (DNA). (medlineplus.gov)
  • Breast cancer that is caused by inherited genetic changes is called hereditary breast cancer. (medlineplus.gov)
  • There are also certain genetic changes that can raise your risk of breast cancer, including changes in the BRCA1 and BRCA2 genes. (medlineplus.gov)
  • Logistic regression was used to assess the genetic association between the occurrence and progression of breast cancer. (nih.gov)
  • NSGC practice guideline: risk assessment and genetic counseling for hereditary breast and ovarian cancer. (blogspot.com)
  • Given the genetic variations in risk factors that exist between different races, we therefore aimed to develop and validate a tool for breast cancer risk assessment among Sudanese women. (biomedcentral.com)
  • Discovery, Biology, and Risk of Inherited Variants in Breast Cancer (DRIVE) was one of five projects funded in 2010 as part of the NCI's Genetic Associations and Mechanisms in Oncology (GAME-ON) initiative ( http://epi.grants.cancer.gov/gameon/ ). (nih.gov)
  • Genetic variants in interleukin genes are associated with breast cancer risk and survival in a genetically admixed population: the Breast Cancer Health Disparities Study. (cdc.gov)
  • This is a systematic review of studies in the PubMed database to April 2013, which fit the eligibility criterion of "Inflammatory Breast Neoplasms" (MeSH Terms), filtered by Languages (English OR Portuguese OR Spanish). (bvsalud.org)
  • To determine whether treatment with alpelisib plus fulvestrant prolongs progression-free survival compared to fulvestrant and placebo in men and postmenopausal women with hormone receptor positive (HR+), HER2- negative advanced breast cancer, who received prior treatment with an Aromatase Inhibitor either as (neo)adjuvant or for advanced disease. (clinicaltrials.gov)
  • 2014. Cognitive function after the initiation of adjuvant endocrine therapy in early-stage breast cancer: an observational cohort study. . (ucla.edu)
  • 2013. The association between pro-inflammatory cytokines, regional cerebral metabolism, and cognitive complaints following adjuvant chemotherapy for breast cancer. . (ucla.edu)
  • In the adjuvant setting, a high level of TILs is associated with better response to trastuzumab, and an abundant number of TILs is an independent prognostic factor in HER2-positive breast cancer [ 3 ]. (e-crt.org)
  • In the pediatric population, lymphoma and rhabdomyosarcoma are the most common sources of NMMN in the breast. (basicmedicalkey.com)
  • Increased susceptibility to infection and the possible development of lymphoma and other neoplasms may result from the increase in the degree of immunosuppression in transplant patients. (rxlist.com)
  • Some breast cancer cells go into apoptosis when treated with Smac mimetics whereas other cells need an additional apoptosis trigger for Smac mimetics to be effective. (lu.se)
  • Down Regulation of CLDND1 Induces Apoptosis in Breast Cancer Cells. (lu.se)
  • This article presents the incidence of female breast cancer in the Gulf Cooperation Council [‎GCC]‎ countries and reviews the data in relation to established reproductive factors. (who.int)
  • Prevention of breast cancer / Ian S. Fentiman. (who.int)
  • Oral contraceptives & breast cancer / Committee on the Relationship between Oral Contraceptives and Breast Cancer, Institute of Medicine, Division of Health Promotion and Disease Prevention. (who.int)
  • The Alberta Physical Activity and Breast Cancer Prevention (ALPHA) Trial was designed to increase the understanding of the biological mechanisms that mediate the inverse association between physical activity and breast cancer risk. (nature.com)
  • from the analysis emerged the theme, development of women's autonomy for the prevention of breast cancer. (bvsalud.org)
  • Familial breast cancer: classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer. (blogspot.com)
  • For example, additional 'Histopathology' information could be added to most of the Neoplasm categories but it cannot be added to the categories elsewhere in the classification. (who.int)
  • Eighty-eight women presenting with locally advanced or metastatic breast cancer were treated with tamoxifen alone. (who.int)
  • This research is to evaluate the effectiveness of Talazoparib as a potential treatment for metastatic breast cancer with a BRCA 1 or BRCA 2 mutation. (clinicaltrials.gov)
  • The U.S. Food and Drug Administration (FDA) has not approved talazoparib for the participants' specific disease but it has been approved for metastatic breast cancer with a germline (inherited) BRCA mutation. (clinicaltrials.gov)
  • 2015. Living with Metastatic Breast Cancer. . (ucla.edu)
  • The present study determined the impact of an important promoter polymorphism (A-202C, rs2854744) on susceptibility and progression of breast cancer in a Chinese population. (nih.gov)
  • Our results suggest that the functional IGFBP3 A-202C polymorphism may influence the susceptibility and progression of breast cancer in the Chinese population. (nih.gov)
  • We estimated survival rate at 9 years of all [‎470]‎ women with breast cancer diagnosed at Salah Aza‹ez Institute of Cancer in Tunis to identify the main prognosis factors. (who.int)
  • Hazard ratios and 95% confidence intervals for associations with 10-year breast cancer-specific survival were estimated in Cox proportional-hazard models. (elsevier.com)
  • The main aim of this study is to find out the various histopathological patterns and distribution of neoplastic breast lesions in various age groups in our institute. (patholjournal.com)
  • What are the signs and symptoms of breast cancer? (medlineplus.gov)
  • In its early stages, breast cancer usually does not cause pain and may exhibit no noticeable symptoms. (icdlist.com)
  • 2015. Depressive episodes, symptoms, and trajectories in women recently diagnosed with breast cancer. . (ucla.edu)
  • 2015. Symptoms and Symptom Attribution Among Women on Endocrine Therapy for Breast Cancer. . (ucla.edu)
  • 2014. Cancer-related intrusive thoughts predict behavioral symptoms following breast cancer treatment. . (ucla.edu)
  • The treatment includes correction of breast asymmetries by using silicone breast implants in patients without cardiopulmonary symptoms, only with esthetic complaints. (rbcp.org.br)
  • This is a multicenter, observational, retrospective, cross-sectional study conducted in breast clinics of Bashaier University Hospital (BUH) and Khartoum Center for Radiation and Isotopes (RICK), Khartoum, Sudan. (biomedcentral.com)
  • US Preventive Services Task Force guidelines recommend BRCA1/2 mutation testing for women at a high risk of CA breast [ 7 ]. (biomedcentral.com)
  • Women with BRCA1 gene mutation have 80% to get breast cancer before the age of 70 and 63% of them would get ovarian cancer before the age of 70. (knowcancer.com)
  • Aberrant FN expression was associated with poor prognosis in patients with luminal type A breast cancer. (elsevier.com)
  • The prognosis of HER2-positive breast cancer has dramatically improved because of introduction of trastuzumab, a humanized monoclonal antibody targeting the extracellular domain of HER2. (e-crt.org)